Health & bio
Every item from Trenri daily that fell into Health & bio, latest first.
June 2026 Β· 110
DRC Ebola Bundibugyo Virus: WHO Maintains International Health Emergency
The International Public Health Emergency of Concern (PHEIC) declared by WHO in May remains in effect. WHO reports 515 confirmed cases and 91 deaths in Congo, 19 confirmed cases in Uganda, with no approved vaccines or treatments.
US Measles Cases Reach 2,134 with Outbreaks in 41 States
According to the CDC, as of June 25, US measles cases have reached 2,134 across 41 states, with 93% linked to outbreak clusters. The unvaccinated share stands at 92%.
FDA Approves Utebzi, First Oral Carbapenem Antibiotic for Complex UTIs
The FDA approved the oral carbapenem antibiotic Utebzi (tebipenem pivoxil) for complex urinary tract infections on June 17. It marks the first US approval of an orally administered carbapenem-class drug.
Ebola Bundibugyo Virus: 1,118 Confirmed, 291 Deaths in DRC
With WHO having declared a PHEIC on May 17, the DRC reported 1,118 confirmed cases and 291 deaths as of June 25. One imported case was confirmed in France, and no licensed vaccines or treatments exist for this variant.
U.S. Measles Cases Reach 2,134 β 30th Outbreak Confirmed
U.S. measles cases totaled 2,134 as of June 25, according to the CDC. There have been 30 outbreaks this year, with 1,982 cases β 93% of the total β linked to outbreak clusters.
Biopharma M&A Tops $134B in H1 2026 β Already Exceeds Full-Year 2025
H1 2026 pharma and biotech M&A volume has already surpassed the full-year 2025 total, according to STAT News. There were 33 biotech acquisitions above $1 billion, totaling approximately $134 billion.
FDA PDUFA Review Target Date for Sobi's Gout Drug NASP Is Today
The FDA's PDUFA target review date for Swedish biotech Sobi's nanocapsulated sirolimus and pegadricase combination therapy (NASP) is June 27, 2026. NASP is a combination therapy designed to lower uric acid levels in patients with refractory gout.
FDA Approves Keytruda + Trodelvy as First-Line Triple-Negative Breast Cancer Treatment
On June 25, the FDA approved the combination of Keytruda and Trodelvy as a first-line treatment for PD-L1-positive metastatic triple-negative breast cancer, based on ASCENT-04 trial data. It is the first combination approval of its kind in this class.
AbbVie to Acquire Apogee for $10.9B, Adding Atopic Dermatitis and Asthma Pipeline
AbbVie entered into an agreement on June 22 to acquire Apogee Therapeutics, which holds IL-13-targeting monoclonal antibody zumlilokibart, for $135.11 per share totaling $10.9 billion.
Psilocybin Drug Receives FDA Commissioner's National Priority Review Voucher
Compass Pathways' synthetic psilocybin COMP360 received an FDA Commissioner's National Priority Review Voucher, shortening the review timeline. Both Phase 3 trials COMP005 and COMP006 for treatment-resistant depression met their primary endpoints.
National Bio Big Data of 770,000 People to Open Gradually in Second Half of 2026
The government will open its national integrated bio big data of 770,000 people starting in the second half of 2026. AI medical startup support vouchers will also expand dramatically from 8 to 40, accelerating AI-driven healthcare innovation.
Severe Alopecia Areata Treatment Covered by National Health Insurance from June
The Ministry of Health and Welfare began covering the severe alopecia areata treatment 'Olumiant (baricitinib)' under national health insurance from June 1. A public forum on extending coverage to youth with general hair loss is also scheduled for July.
South Korea Joins International Clinical Trial Network β Strengthening Pandemic Response
Four hospitals including Seoul National University Bundang Hospital are participating in a multi-national RAPID clinical trial targeting antibiotic-resistant bacteria. Linked with the NIH-led STRIVE program, the effort raises South Korea's infectious disease response capabilities to international standards.
Semaglutide Slows Biological Aging by 9%, First RCT Confirms
A UC San Diego team published in Nature Communications showing weekly semaglutide reduced epigenetic aging speed by 9% versus placebo β the first randomized controlled trial to confirm an anti-aging effect from a GLP-1 drug.
β¦ RELATED STORYLINEIvonescimab Cuts Lung Cancer Mortality by 34% β ASCO Plenary
Akeso and Summit Therapeutics bispecific antibody ivonescimab combined with chemo reduced death risk by 34% in advanced squamous NSCLC as first-line therapy, per the HARMONi-6 trial presented at ASCO.
Wegovy Pill Surpasses 3 Million Prescriptions in 5 Months
Novo Nordisk announced at ADA 2026 that its oral semaglutide 25mg tablet has exceeded 3 million prescriptions, with over 80% going to patients who had never previously received GLP-1 therapy.
β¦ RELATED STORYLINEAbbVie seals $10.9B all-cash Apogee Therapeutics deal
AbbVie sweeps up Apogee Therapeutics for $135.11/share, $10.9B cash. Lead asset zumilokibart (IL-13 target) shores up immunology portfolio post-Humira cliff.
FDA okays first oral carbapenem, Utebzi, for resistant UTIs
Tebipenem pivoxil gets green light for complicated UTI treatment. First oral carbapenem ever. Landmark for antibiotic resistance: serious infections now have oral option.
MoonLake posts Week 52 sonelokimab data; 67% hit HiSCR75
IL-17A/F nanobody sonelokimab: 67% achieved HiSCR75 response in hidradenitis suppurativa; 25%+ full remission. BLA target 2026.
WHO flags AI policy risks; human-in-loop critical, algorithm audit urged
Discussion paper unpacks how AI reshapes evidence-based health policy beyond clinical. Mandatory algorithmic impact assessments, human validation loop, deployment readiness checks recommended.
APG273 dual IL-13/TSLP inhibitor gains attention from Apogee deal
Alongside single-target zumilokibart, Apogee's APG273 blocks both IL-13 and TSLP cytokines in one long-acting antibody. Dual blockade shows asthma severity edge over monotherapy.
K-Pharma-Biotech H1 Technology Transfer Breaks 13 Trillion Won
With Oscotec's autoimmune disease therapy technology transfer to US Azios at up to 1 trillion won scale and other deals, domestic biotech companies' first-half 2026 global licensing-out exceeded 13 trillion won, rebounding versus the same period last year.
Korea's First Advanced Regenerative Medicine Therapy Approved for Rare Lymphoma Patients
The Ministry of Health and Welfare approved a treatment plan for EBV-positive rare NK/T-cell lymphoma patients using autologous immune cell injection as the first approved advanced regenerative medicine therapy. The first approval 14 months after system implementation raises access to rare disease treatment.
HLB Ribociclib FDA Decision Date Confirmed July 23 for Liver Cancer Indication
HLB's FDA decision date for ribociclib and camrelizumab combination therapy co-filed with Antengene Pharma is confirmed for July 23. After two Requests for Additional Information, the third attempt is underway, with HLB Chair Jin Yang-gon expressing hopes for simultaneous approval of two anti-cancer drugs in the second half.
FDA issues Complete Response Letter to cytisinicline β approval delayed
The FDA sent a Complete Response Letter to cytisinicline on its June 20 PDUFA date, declining to approve the smoking cessation drug due to manufacturing facility GMP issues. Developer Achieve Life Sciences plans to refile in Q4 2026 with a new manufacturing partner.
Ebola Bundibugyo PHEIC drags on β Korea tightens border screening at arrival gates
The WHO-declared Public Health Emergency of International Concern for Ebola Bundibugyo continues, with 837 confirmed cases and 196 deaths across DRC and Uganda as of June 15. Korea's KDCA is maintaining a 'Watch' alert and conducting universal screening at arrival gates for travelers from the affected countries.
GLP-1 users walk 560 fewer steps per day β exercise still essential alongside the drugs
A study presented at ENDO 2026 found that people taking GLP-1 weight-loss drugs such as Ozempic and Wegovy walked an average of 560 fewer steps per day and spent 5.7 fewer minutes in moderate-intensity activity. Experts are urging patients to maintain resistance training to prevent muscle loss.
Cytisinicline FDA PDUFA today β first new quit-smoking drug in 20 years
Achieve Life Sciences' cytisinicline hits its FDA PDUFA deadline today (6/20). Phase 3 trials ORCA-2 and ORCA-3 demonstrated significant smoking cessation rates vs placebo in over 2,000 participants. It would be the first new mechanism since varenicline.
Wegovy pill tops 3 million prescriptions β oral GLP-1 market explodes
Novo Nordisk's Wegovy pill hit 3 million prescriptions and Q1 revenue of $355M β twice the forecast β just 5 months after launch. Eli Lilly's orforglipron (Foundayo), approved in April, is intensifying competition in the oral GLP-1 space.
β¦ RELATED STORYLINEFDA's June oncology relay β KRAS and AKT1 targeted therapies surge to the fore
In June, the FDA is reviewing expanded approval of the KRAS-targeted pancreatic cancer drug daraxonirasiB and fast-track status for the AKT1 inhibitor TER-2013 in HR+ breast cancer. Q2 2026 is shaping up as a turning point for the oncology landscape.
Ebola cases in DRC reach 837 confirmed, 196 deaths, WHO activates emergency response as Uganda spread confirmed
Bundibugyo virus Ebola outbreak expanded to three provinces in DRC β Ituri, North Kivu, and South Kivu β with 837 confirmed cases and 196 deaths as of June 15. 19 cases confirmed in Uganda, with WHO and U.S. CDC mobilizing emergency response plans exceeding $500 million as no designated treatments or vaccines exist.
New smoking cessation drug in 20 years imminent...FDA decision on cytisinicline tomorrow
The FDA PDUFA decision date for Achieve Life Sciences' plant-derived smoking cessation drug cytisinicline is June 20. Upon approval, the first new smoking cessation treatment since varenicline 20 years ago will be born. ORCA-2 and ORCA-3 trials confirmed meaningful smoking cessation rate improvements over placebo.
AstraZeneca's oral GLP-1 elecoglipron achieves 10.5% weight loss in 26 weeks, Phase III underway
Elecoglipron 75mg presented at ADA 2026 achieved 10.5% weight loss in 26 weeks (placebo 0.6%), with results published in Lancet. As a once-daily oral small molecule GLP-1 receptor agonist with no food or fasting restrictions, EMBOLD and ELUMINATE Phase III trials have officially begun.
β¦ RELATED STORYLINEDRC Ebola reaches 782 cases and 181 deaths, WHO maintains PHEIC as Uganda hit
The DRC's Ebola Bundibugio virus outbreak has reached 782 confirmed cases and 181 deaths as of June 14. Ituri Province accounts for 717 cases and Uganda has reported 19 additional cases. The WHO, which declared a PHEIC on May 17, continues its emergency response.
Smoking cessation drug cytisinicline heads for FDA decision D-3 on June 20
The FDA PDUFA review date for cytisinicline β a plant-derived alkaloid smoking cessation drug β is June 20. The first novel cessation therapy since varenicline, it demonstrated significantly higher quit rates than placebo in Phase 3 ORCA-2 and ORCA-3 trials and holds FDA Breakthrough Therapy designation.
Oral GLP-1 elecoglipron achieves 10.5% weight loss at 26 weeks, enters Phase 3
At ADA 2026, AstraZeneca's oral small-molecule GLP-1 receptor agonist elecoglipron 75mg achieved 10.5% body weight reduction at 26 weeks. 88.8% of participants lost at least 5% versus placebo; results were published in The Lancet and the drug has advanced to Phase 3 EMBOLD.
β¦ RELATED STORYLINEEbola Cases Surge to 782 in DRC β WHO Warns PHEIC to Continue
The Ebola Bundibugyo virus outbreak in the Democratic Republic of Congo has worsened to 782 confirmed cases and 181 deaths as of June 14. Ituri Province accounts for 717 cases and Uganda reported 19. WHO, which declared a PHEIC on May 17, is warning of further regional spread if the trend continues.
Oral GLP-1 Drug Delivers 10.5% Weight Loss in Trial β Potential Obesity Game-Changer
At the ADA annual conference, AstraZeneca's oral GLP-1 receptor agonist elecoglipron delivered meaningful blood sugar reduction and 10.5% weight loss over 26 weeks in a type-2 diabetes trial. Eli Lilly's orforglipron also proved superior in three Phase 3 trials, heralding an era of injection-free obesity treatment.
β¦ RELATED STORYLINEFirst New Smoking Cessation Drug in 20 Years, Cytisinicline, Faces FDA Decision D-4
The plant-derived nicotine receptor partial agonist cytisinicline faces its FDA PDUFA date on June 20. Phase 3 ORCA-2 and ORCA-3 trials showed significantly higher quit rates than placebo; FDA already granted Breakthrough Therapy designation. Approval would be the first new smoking cessation drug since varenicline in 2006.
WHO Ebola PHEIC: 676 Cases, 136 Deaths in DRC and Uganda
WHO declared Ebola Budibugyo virus a Public Health Emergency of International Concern on May 17. As of June 10, there are 676 confirmed cases and 136 deaths. The Africa CDC and WHO have launched a $518 million emergency response plan.
FDA Approves Belzutifan + Pembrolizumab as First Adjuvant for Renal Cell Carcinoma
On June 12, the FDA approved the belzutifan + pembrolizumab combination as adjuvant therapy for high-risk clear-cell renal cell carcinoma after radical nephrectomy, based on the LITESPARK-022 trial (1,841 patients). The first dual HIF-2Ξ±/PD-1 inhibition approval.
Cytisinicline, First New Smoking-Cessation Drug in 20 Years, Faces FDA Decision June 20
The plant-derived alkaloid cytisinicline demonstrated significant quit rates vs. placebo in the ORCA-2 and ORCA-3 Phase 3 trials. Its FDA PDUFA date is June 20. If approved, it would be the first new smoking-cessation drug since varenicline in 2006.
China's JUNO Neutrino Observatory Publishes First Results on Nature Cover
The JUNO observatory, which holds 20,000 tonnes of liquid 700 meters underground, successfully reduced uncertainty in neutrino oscillation parameters by 1.6x compared to previous measurements using 59 days of data. The results were published as the cover paper in the June 10, 2026 issue of Nature.
Finerenone Shows Cardio-Renal Protection in Non-Diabetic CKD; Published in 3 Journals Simultaneously
Clinical studies published simultaneously in NEJM, JAMA, and The Lancet showed finerenone reduced the risk of kidney failure and cardiovascular death in non-diabetic chronic kidney disease patients by 23%. This opens a new treatment option for millions who had limited choices.
Stanford Successfully Regenerates Knee Cartilage by Blocking Aging Protein 15-PGDH
A Stanford Medical School research team successfully regenerated damaged knee cartilage in elderly mice and prevented arthritis by blocking the aging protein 15-PGDH. An oral drug has already entered clinical trials.
WHO declares Ebola Bundibugyo PHEIC; 635 confirmed, 127 dead in DRC
The WHO declared the Ebola Bundibugyo virus outbreak in the DRC and Uganda a Public Health Emergency of International Concern on May 17, 2026. As of June 10, the DRC alone reports 635 confirmed cases and 127 deaths, with no approved vaccine or treatment.
US measles reaches 2,073 cases across 40 jurisdictions in 2026
As of June 11, the US 2026 measles total stands at 2,073 cases across 40 jurisdictions, led by South Carolina (668). Some 92% of confirmed cases involve unvaccinated individuals, and 72% are children and adolescents.
Eli Lilly retatrutide hits 28.3% weight loss in TRIUMPH-1 Phase 3 β a new record
Eli Lilly announced TRIUMPH-1 Phase 3 results in May 2026: weekly 12mg retatrutide over 80 weeks produced an average 28.3% body weight reduction (~32 kg), with 45% of participants losing more than 30%, setting a new obesity drug benchmark.
β¦ RELATED STORYLINENovo Nordisk CagriSema under FDA review; 22.7% weight loss in pivotal trial
Novo Nordisk submitted its CagriSema NDA to the FDA in December 2025, with an H2 2026 decision expected. The REDEFINE 1 Phase 3 showed 22.7% weight reduction and REIMAGINE 2 showed 1.91 percentage-point HbA1c improvement in diabetes patients.
β¦ RELATED STORYLINEFDA approves 4 drugs in May 2026, including rare blood cancer and COVID-19 prevention
The FDA approved Gilead's decnupazab for BPDCN, a hepatitis B/D treatment (Hepcludex), a triple-negative breast cancer therapy (DATROWAY), and Shionogi's COVID-19 prevention agent Xocova in May 2026.
Orforglipron wins FDA nod as the first GLP-1 pill with no food or timing limits
The FDA approved Lilly's orforglipron for adult obesity on April 1. Unlike oral semaglutide, it can be taken any time without food or water, promising better adherence, and ADA 2026 phase-3 data showed double-digit weight loss over 72 weeks.
β¦ RELATED STORYLINEBundibugyo Ebola hits 635 cases across DRC and Uganda; WHO declares a PHEIC
The Bundibugyo outbreak has spread across 18 health zones in DRC's Ituri and into Uganda, with 635 cases and 127 deaths as of June 9. The WHO declared a PHEIC on May 17; with no approved vaccine and a 30-50% fatality rate, response gaps are exposed.
US measles tops 2,030 cases, with elimination loss called 'highly likely'
US measles reached 2,030 cases by June 4, near the highest since 1991, with 30 large outbreaks across Florida, Pennsylvania and Virginia as MMR coverage slipped to 92.5%. CIDRAP calls a fall loss of elimination status highly likely.
Retatrutide phase 3 cuts A1C 2.0 points and sleep apnea 61% at ADA 2026
At ADA 2026, the triple agonist retatrutide cut baseline A1C of 7.9% by up to 2.0 points, reduced sleep-apnea events 60.6% and knee-osteoarthritis pain 73.1%, proving broad comorbidity benefit and shifting Lilly's obesity pipeline.
β¦ RELATED STORYLINECytisinicline FDA decision due June 20, the first new quit-smoking drug in 20 years
The plant-derived nicotine-receptor partial agonist cytisinicline faces a June 20 PDUFA date; approval would mark the first new smoking-cessation drug since varenicline in 2006. ORCA-2 and -3 showed higher quit rates, and the FDA granted priority review.
Bundibugyo Ebola at 598 cases in DRC, WHO/Africa CDC mount 500M response
As of June 8, the DRC reported 598 Bundibugyo Ebola cases and 115 deaths, with Uganda at 19 and 2. WHO and Africa CDC unveiled a 518-million-dollar joint response, and CEPI committed 60 million to three vaccine candidates.
Lilly's retatrutide sets record with 28.3% average weight loss at 80 weeks
Lilly's triple agonist retatrutide delivered an average 28.3% (about 31.9 kg) weight loss at 80 weeks in the 12mg arm of the TRIUMPH-1 Phase 3. It is the best obesity-drug result yet, with an FDA filing targeted for late 2026.
β¦ RELATED STORYLINENovo CagriSema REIMAGINE Phase 3 proves HbA1c and weight cuts
Novo's CagriSema achieved a 1.8-point HbA1c drop and 13.8% weight loss at 40 weeks in the 2.4mg arm of the REIMAGINE Phase 3 presented at ADA 2026. It met all primary and secondary endpoints, proving combination potential in diabetes.
β¦ RELATED STORYLINEUS measles tops 2,030, elimination status at risk after 26 years
As of June 4 US measles cases reached 2,030 across 30 outbreaks, with 93% unvaccinated. CIDRAP warned it is 'highly likely' the US loses its elimination status at this fall's PAHO review, ending a 26-year run.
Oral GLP-1 orforglipron's diabetes data debuts at ADA 2026
Diabetes trial data for orforglipron, the oral GLP-1 the FDA approved April 1, debuted at ADA 2026 in June. As the first non-peptide oral agent taken without food restrictions, it showed up to 12.4% weight loss at 72 weeks.
β¦ RELATED STORYLINELilly's retatrutide sets record with 28% average weight loss
In the TRIUMPH-1 phase 3 unveiled at ADA 2026, Lilly's triple agonist retatrutide cut weight 28.3% on average at 80 weeks in the 12mg arm. 45.3% lost 30%-plus, a new high for obesity drugs.
β¦ RELATED STORYLINENovo's CagriSema REIMAGINE phase 3 hits all primary endpoints
Novo Nordisk's CagriSema met all primary endpoints in the REIMAGINE 1, 2 and 3 phase 3 trials presented at ADA 2026. Trial 2 showed a 1.91-point HbA1c drop and 14.2% weight loss at 68 weeks.
β¦ RELATED STORYLINEBundibugyo Ebola emergency: over 530 cases in DRC and Uganda
The Bundibugyo Ebola outbreak, declared a WHO emergency on May 17, rose to 515 cases in DRC and 19 in Uganda by early June. Deaths reached about 90, with no approved vaccine or therapy, leaving only supportive care.
US measles tops 2,030, risking elimination status after 26 years
US measles cases reached 2,030 as of June 4, with 30 new outbreaks reported. Falling MMR coverage fueled spread, and officials warned the US could lose its elimination status at a November PAHO review.
FDA approves oral post-exposure COVID drug Xocova in May
On May 29 the FDA approved Shionogi's ensitrelvir (Xocova) as the first oral antiviral for post-exposure COVID-19 prevention. The 3CL protease inhibitor can be taken within 72 hours of exposure.
Lilly's retatrutide sets record with 30% average weight loss in Phase 3
Per ADA 2026, Lilly's triple agonist retatrutide in the TRIUMPH-1 Phase 3 trial achieved 28.3% average weight loss at week 80 in the 12mg arm, and 30.3% (about 38.6kg) at week 104 for BMI 35+, a new obesity-drug record.
Novo's CagriSema fails non-inferiority vs Zepbound at week 84 head-to-head
In the REDEFINE 4 head-to-head trial unveiled at ADA 2026, Novo's CagriSema 2.4mg posted 23% weight loss at week 84 but failed its primary endpoint of non-inferiority versus tirzepatide 15mg. A US FDA decision is expected by year-end.
DRC-Uganda Bundibugyo Ebola spreads to 400 cases, 66 deaths
The Bundibugyo Ebola outbreak, declared a PHEIC by the WHO on May 17, persisted into June, reaching 381 cases and 64 deaths in the DRC and 19 cases and 2 deaths in Uganda per a June 4 tally. No vaccine or treatment exists for this strain.
US measles tops 2,030 cases, elimination status at risk after 25 years
Per the CDC, US measles cases in 2026 topped 2,030 as of June 4, with 30 new outbreaks reported. 92% of patients were unvaccinated and 6% hospitalized. A November PAHO review is likely to revoke the elimination status earned in 2000.
Novo's zenagamtide, a GLP-1/amylin combo diabetes drug, shows 14.6% weight loss
Per Phase 2 results of Novo's zenagamtide (amycretin) at ADA 2026, the top dose achieved 14.6% weight loss and a 1.71-point A1C improvement at week 36 in 262 type 2 diabetes patients. The company plans to begin Phase 3 in the second half.
Ebola Bundibugyo variant declared PHEIC; spread continues despite response
The WHO declared the Bundibugyo ebolavirus outbreak in the DRC and Uganda a PHEIC on May 17. As of June 3, the DRC reported 381 confirmed cases and 64 deaths, with existing treatments proving ineffective and contact tracing at only 45%, hampering containment efforts.
β¦ RELATED STORYLINEUS measles cases exceed 2,030; elimination status at risk by fall
Cumulative measles cases in the US have exceeded 2,030 across 40 states, with 30 outbreaks reported. Over 92% of confirmed cases involved unvaccinated individuals, raising alarm that the nation may lose its measles-free status by fall as MMR vaccination rates decline.
ADA 2026: Novo's Cagrisema achieves 23% weight loss at 84 weeks
At ADA 2026 (June 5-8, New Orleans), Novo Nordisk presented Cagrisema phase 3 results. The drug achieved 23% weight loss at 84 weeks, falling short of Eli Lilly's Zepbound (25.5%).
β¦ RELATED STORYLINEFDA approves Eli Lilly's oral GLP-1 Orforglipron for obesity treatment
The FDA approved Eli Lilly's oral GLP-1 obesity treatment Orforglipron on April 1. As the world's first non-peptide oral GLP-1, taken once daily without food restrictions, phase 3 trials showed average weight loss exceeding 12%.
β¦ RELATED STORYLINEOral Wegovy pills launch in US at 149 dollars monthly, transforming GLP-1 access
Novo Nordisk's oral semaglutide (Wegovy pills) launched in the US market starting January. At 149 dollars per month, superior accessibility compared to injections is expected to reshape the GLP-1 landscape, with extensive data presented at ADA.
β¦ RELATED STORYLINEUS measles cases hit 2,030 this year, nearing 2025 record, shaking elimination status
As of June 4, US measles cases this year reached 2,030, nearing the record 2,288 of 2025. Over 92% of patients are unvaccinated and 6% (127) were hospitalized; 30 new clusters across four states threaten elimination status.
Innovent's IBI343 meets Phase 3 primary endpoint in gastric cancer; China NDA accepted
On June 4 Innovent Biologics said its CLDN18.2-targeting ADC IBI343 met the primary endpoint in an international Phase 3 trial for advanced refractory gastric cancer. China's NMPA accepted the NDA; it is the first CLDN18.2 ADC under regulatory review worldwide.
FDA approves oral Covid post-exposure prophylactic ensitrelvir (Xocova)
On May 29 the FDA approved Shionogi's ensitrelvir (Xocova) for Covid-19 post-exposure prophylaxis (PEP). A Phase 3 trial showing significantly lower onset risk by day 10 versus placebo was the basis; it is the first oral option for PEP.
First smoking-cessation drug in 20 years: cytisinicline FDA decision by June 20
An FDA decision on the plant-derived alkaloid smoking-cessation drug cytisinicline is due by June 20. Phase 3 trials ORCA-2 and ORCA-3 showed significantly higher quit rates versus placebo; if approved it would be the first new cessation drug in about 20 years.
FDA approves Lilly's oral obesity drug orforglipron, its fastest NME ever
The FDA approved the oral obesity drug orforglipron (Foundayo) as the first new molecular entity under the National Priority Voucher program. The decision came 50 days after filing and 294 days ahead of the PDUFA date, the fastest NME approval since 2002.
β¦ RELATED STORYLINEWHO and Africa CDC unveil a joint $518M six-month Ebola response plan
WHO and Africa CDC unveiled a joint six-month continental plan to fight Bundibugyo Ebola on June 5, targeting a $518 million budget for June-November 2026.
Ebola: DRC 381 cases, Uganda 19; WHO DON605 updates the latest status
Per WHO DON605 dated June 5, the DRC has 381 confirmed cases (64 deaths) and Uganda 19 (2 deaths), with Ituri province accounting for all 359 cases as cross-border spread continues.
Abemaciclib delivers first phase 3 liposarcoma win, PFS 9.7 months in SARC041
Presented in an ASCO 2026 plenary, the phase 3 SARC041 showed abemaciclib cut progression or death risk 62% in advanced dedifferentiated liposarcoma, with median PFS of 9.7 months versus 1.5 on placebo, the first positive phase 3 in the tumor type.
FDA accepts ivonescimab BLA, PDUFA Nov 14; first US review for PD-1/VEGF bispecific
The FDA accepted ivonescimab's (a PD-1/VEGF bispecific) BLA for second-line-plus EGFR-mutated non-small-cell lung cancer and set a review date of November 14, 2026, after the phase 3 HARMONi cut progression risk 48%.
ADA 2026 opens; Novo Nordisk unveils full CagriSema phase 3 data on June 7
The American Diabetes Association 2026 sessions opened June 5 in New Orleans. Novo Nordisk will present full CagriSema REIMAGINE phase 1-3 data on June 7, after REIMAGINE 2 showed a 1.91-point HbA1c drop and 14.2% weight loss.
β¦ RELATED STORYLINEPancreatic drug daraxonrasib doubles survival in second line
In the ASCO 2026 plenary, the phase 3 RASolute 302 trial (500 patients) showed daraxonrasib doubled median overall survival to 13.2 months vs 6.7 for chemo (HR 0.40), with simultaneous NEJM publication, likely a new 2nd-line standard.
Ivonescimab improves survival in first-line squamous lung cancer
In the 532-patient HARMONi-6 phase 3, the PD-1/VEGF bispecific ivonescimab plus chemo cut death risk 34% vs tislelizumab plus chemo (HR 0.66). It is the first China-originated cancer drug chosen for an ASCO plenary.
Galleri blood test misses primary endpoint but cuts stage IV 26% in first RCT
In the 142,250-person NHS-Galleri study over three years, the primary endpoint for stage III/IV diagnoses missed significance. But stage IV diagnoses fell 26% by year three, suggesting earlier detection, with fewer emergency diagnoses.
Abemaciclib scores first phase 3 win in rare liposarcoma, cutting risk 62%
In the 108-patient SARC041 phase 3, the CDK4 inhibitor abemaciclib extended median PFS in dedifferentiated liposarcoma to 9.7 months vs 1.5 for placebo, a 62% risk cut (HR 0.38) β the first positive phase 3 in the disease.
CEPI puts $62M into Ebola PHEIC, fast-tracking three vaccines
With Bundibugyo Ebola spreading in Congo and Uganda (900+ suspected, 220+ deaths), the WHO declared a PHEIC on May 16. On June 1, CEPI announced $62M total to fast-track three vaccines from Moderna, IAVI and Oxford.
Daraxonrasib nearly doubles pancreatic-cancer survival, ASCO ovation
In the RASolute 302 phase 3, daraxonrasib lifted median survival in pretreated metastatic pancreatic cancer to 13.2 months (chemo 6.7), cutting death risk 60%. Presented at ASCO June 1, published simultaneously in NEJM.
Ivonescimab plus chemo beats PD-1 on survival in squamous lung cancer
In HARMONi-6, ivonescimab combo lifted first-line squamous NSCLC survival to 27.89 months vs tislelizumab's 23.69, cutting death risk 34% (HR 0.66). It is the first China-developed drug picked for an ASCO plenary.
Abemaciclib delivers first phase-3 win in liposarcoma, 62% risk cut
In SARC041, abemaciclib achieved progression-free survival of 9.7 months (placebo 1.5) in advanced dedifferentiated liposarcoma, cutting progression/death risk 62% β the first positive phase 3 in this rare sarcoma.
β¦ RELATED STORYLINEGalleri multi-cancer blood test cuts stage-IV diagnoses up to 26% in first RCT
In the 142,942-person NHS-Galleri trial, stage-IV diagnoses fell 9%, 22% and 26% across three screening rounds, with stage-I/II diagnoses up 16% β the first randomized controlled trial of multi-cancer early detection.
β¦ RELATED STORYLINEDRC-Uganda Ebola PHEIC: CEPI accelerates 3 vaccines with $62M
On May 17 the WHO declared the Bundibugyo Ebola outbreak a PHEIC. On June 1 CEPI urgently accelerated three vaccine programs with $50m to Moderna, $8.6m to Oxford and $3.2m to IAVI.
Daraxonrasib lifts metastatic pancreatic OS to 13.2 months
In the RASolute 302 Phase 3, daraxonrasib delivered median overall survival of 13.2 months, nearly double chemotherapy's 6.7 months. It headlined the ASCO 2026 plenary with an NEJM publication.
FDA approves vepdegestrant, the world's first PROTAC cancer drug
Arvinas and Pfizer's vepdegestrant won FDA approval May 1 for ESR1-mutated ER-positive, HER2-negative metastatic breast cancer, the first-ever PROTAC-class drug.
Bundibugyo Ebola declared a PHEIC in DRC and Uganda
The WHO declared the DRC-Uganda Bundibugyo Ebola outbreak a public health emergency on May 17. As of June 2 there are 336 confirmed cases and 49 deaths, with no approved vaccine.
Oral Wegovy pill launches in US, speeding GLP-1 access
Novo Nordisk's oral semaglutide launched in the US after FDA approval. The OASIS 4 trial showed 16.6% weight loss, and a $149 monthly price sharply widens access.
β¦ RELATED STORYLINEKEYNOTE-522 final analysis: early-TNBC 7-year survival 85%
KEYNOTE-522 final data at ASCO 2026 showed 85.1% 7-year overall survival in the pembrolizumab arm versus 77.2% for placebo, reaffirming the standard of care for early TNBC.
β¦ RELATED STORYLINEPancreatic daraxonrasib doubles OS to 13.2 months at ASCO plenary
Revolution Medicines' oral RAS inhibitor daraxonrasib extended median OS for previously treated metastatic pancreatic cancer to 13.2 months versus chemotherapy's 6.6 in the RASolute 302 trial, presented at the May 31 ASCO plenary and published in NEJM.
TNBC pembrolizumab reaffirms standard with 85.1% 7-year survival
KEYNOTE-522's final analysis showed a 7-year overall survival of 85.1% for the pembrolizumab combo in high-risk early triple-negative breast cancer, versus 77.2% for placebo (8pp gain). Follow-up was 93.8 months across 1,174 patients, presented at ASCO 2026.
FDA approves first PROTAC cancer drug, vepdegestrant, for breast cancer
On May 1 the FDA approved Arvinas and Pfizer's vepdegestrant for ESR1-mutated, ER-positive, HER2-negative advanced breast cancerβthe world's first approved protein-degrading PROTAC drug, based on the VERITAC-2 trial.
WHO declares Bundibugyo Ebola in Congo, Uganda a PHEIC
On May 17 the WHO declared the Bundibugyo Ebola outbreak in the DRC and Uganda a PHEIC. Cases surged to 282 as of June 1, and with no approved vaccine or therapy, concern is spreading.
GRAIL's Galleri multi-cancer blood test boosts detection up to 6.5x
GRAIL's 35,878-participant PATHFINDER 2, presented at ASCO 2026, showed the Galleri multi-cancer early-detection blood test raised cancers found up to 6.5x over standard screening, with 60.3% positive predictive value and 71% of new cancers at stages 1-3.
Daraxonrasib pancreatic OS 2x, ASCO plenary grand slam
RAS inhibitor daraxonrasib showed in Phase 3 RASolute 302 that median overall survival in metastatic pancreatic cancer reached 13.2 months vs chemotherapy's 6.7 monthsβdoubling itβwith 60% death-risk reduction (HR 0.40) across 500 patients in six countries.
Akeso/Summit ivonescimab squamous lung cancer -34% death risk
Dual PD-1/VEGF antibody ivonescimab in Phase 3 HARMONi-6 cut first-line squamous NSCLC death risk 34% vs tislelizumab plus chemotherapy and extended survival ~4 months. Presented May 31 with US partner Summit benefit.
Lilly selpercatinib early RET lung cancer recurrence risk -83%, NEJM
Phase 3 LIBRETTO-432 showed selpercatinib adjuvant therapy cut early RET-fusion NSCLC recurrence or death risk 83% in 151 patients across 22 countriesβfirst proof in a non-targeted therapy population with simultaneous NEJM publication and ASCO plenary.
WHO Bundibugyo Ebola PHEIC, DRC 125 confirmed, no vaccine
WHO declared May 17 a Public Health Emergency of International Concern for Bundibugyo Ebola across DRC and Uganda. As of May 28, DRC reports 125 confirmed, 17 deaths, 906 suspected; Uganda 9 confirmed with no approved vaccine or treatment.
FDA late-May approvalsΒ·decitabine, boxpendi, durvalumab
FDA approved May 27 CD123-targeted ADC decitabine for BPDCN, May 18 first aldosterone synthase inhibitor boxpendi for hypertension, and May 28 durvalumab plus BCG for high-risk non-muscle-invasive bladder cancer.
May 2026 Β· 136
Lilo & Stitch $182.7M Β· Memorial Day box office record
Disney's 'Lilo & Stitch' live-action remake earned $182.7M over 4 Memorial Day days, setting all-time holiday weekend opening record. Global cumulative reached $361.3M, placing it third in Disney live-action remake openings.
Mission Impossible Final Reckoning franchise-high $77M opening
Mission Impossible The Final Reckoning opened at $77M domestically over 4 days and $190M globally, marking the franchise's best opening. Though #2 to Lilo & Stitch, combined weekend hit $334.5M all-time Memorial Day record.
aespa LEMONADE second album 840K day-one sales
aespa released their second full album 'LEMONADE' on May 29 with double title tracks 'WDA' and 'Lemonade.' On first day of sales, Hanteochart recorded 842,534 units. SM announced 2026-2027 world tour across Asia, Americas, and Europe.
Yeon Sang-ho 'Colony' Cannes Midnight 7-minute standing ovation
Director Yeon Sang-ho's K-zombie thriller 'Colony' received official Midnight Screening invitation at the 79th Cannes Film Festival with 7+ minute standing ovation despite 3 AM screening. His third Cannes entry after 'Train to Busan' and 'Peninsula.'
Mandalorian and Grogu Memorial Day $165M opens #1
Star Wars 'Mandalorian & Grogu' opened May 22 domestically with $102M over 4 days and $165M globally, taking Memorial Day #1 position. CinemaScore 'A-' exceeded 'Rise of Skywalker' 'B+'.
ASCO 2026 Chicago opens 5/29 Β· 7,000 abstracts Β· 35,000 oncologists for Day 1 launch
ASCO's annual meeting opens 5/29 at McCormick Place in Chicago. With 7,000 abstracts, 200+ sessions, and 35,000 oncologists gathering, next-generation immuno-oncology, bispecific antibody, and precision-medicine data simultaneously emerge at weekend plenaries β a decisive oncology market inflection point activates.
Revolution Medicines pancreatic daraxonrasib RASolute 302 OS ~2x improvement looms
Revolution Medicines's pancreatic cancer drug daraxonrasib RASolute 302 OS data will be unveiled at the weekend plenary. A preliminary signal of roughly 2x overall survival improvement is being priced and a $10B market-cap jump scenario already reflected β Day 1 oncology sector momentum ignites.
Summit / Akeso bispecific ivonescimab HARMONi-6 lung first-line treatment data unveiled
Summit Therapeutics / Akeso's bispecific antibody ivonescimab HARMONi-6 lung first-line data is placed at the ASCO plenary. As a PD-1ΓVEGF dual-target next-generation immuno-oncology best-in-class candidate, global immuno-oncology hegemony begins diffusing from Merck Keytruda's near-monopoly.
Lilly Retevmo / Verzenio double plenary Β· LIBRETTO-432 / Sarc041 precision-treatment punch
Lilly grabs Day 1 ASCO momentum with the Retevmo LIBRETTO-432 and Verzenio Sarc041 double plenary. RET-mutant lung and osteosarcoma precision-treatment data emerge simultaneously, with the next stage of oncology precision medicine in view and Merck, BMS, MRNA big-pharma PD-1 diversification competition intensifying.
WHO Bundibugyo Ebola PHEIC spreads Β· DRC 121 cases / 17 deaths Β· Uganda 7, no vaccine
WHO's Bundibugyo Ebola PHEIC, declared 5/17, has spread to DRC 121 confirmed / 17 deaths / 1,077 suspected and Uganda 7 confirmed as of 5/26. Absence of a Bundibugyo-specific vaccine and treatment is the core challenge, with Oxford / Serum Institute's ChAdOx1 monovalent vaccine pushing for clinical entry in 2-3 months.
WHO Bundibugyo Ebola PHEIC escalates; DRC 121 confirmed, Uganda 7; vaccine gap persists
The Bundibugyo Ebola outbreak, declared a PHEIC on 5/17, has escalated to 121 confirmed cases in the DRC with 17 deaths and 1,077 suspected cases as of 5/26, plus seven confirmed in Uganda. The absence of a Bundibugyo-specific vaccine remains the critical bottleneck.
ASCO 2026 annual meeting opens 5/29 in Chicago McCormick Place; 35,000 oncologists, 7,000 abstracts convene
The American Society of Clinical Oncology's annual conference opens 5/29 at McCormick Place. With 35,000 oncologists and 7,000 abstracts across 200+ sessions, next-generation immunotherapy and cancer-care data will move markets in a single week.
FDA approves Novo Nordisk oral semaglutide 25mg for weight loss; first GLP-1 pill with MACE reduction data
Novo Nordisk's oral semaglutide 25mg won FDA approval for obesity and cardiovascular risk reduction, marking the first approved GLP-1 oral. OASIS 4 data showed average 16.6% weight loss. Uninsured pricing begins at $149/month.
β¦ RELATED STORYLINEDOJ appeals ACIP vaccine-policy ruling; RFK Jr.'s board picks flagged with first-circuit appeal filed
The Department of Justice filed an appeal to the First Circuit on the March 16 Murphy ruling that voided Kennedy's ACIP board appointments. The DOJ simultaneously proposes adding toxicology, pediatric neurodevelopment, and vaccine-adverse-event expertise to the councilβa direct collision with pediatric-society standards.
H5N1 human infections surpass 1,000 cumulative cases globally; fatality rate 48%
The CDC has updated cumulative HPAI A(H5N1) human infections across 25 countries since 1997 to over 1,000 cases, with roughly 48% fatality rate. Q1 2026 saw 13 new cases: one pediatric death in Bangladesh, three in Cambodia. WHO has escalated monitoring status.
WHO Bundibugyo Ebola PHEIC, 105 confirmed, 906 suspected, expanding
DRC reported 105 confirmed and 906 suspected cases (223 suspected deaths), Uganda 7 confirmed cases as of 5/26. Spread across Ituri, North Kivu, South Kivu, while Italy's suspected case tested negative showing some partial calming signal.
Oxford Bundibugyo-specific ChAdOx1 vaccine to enter trials in 2-3 months
Oxford University and Serum Institute will accelerate clinical trials of ChAdOx1 BDBV monovalent vaccine for Bundibugyo. However, GMP production requires additional 6-9 months, so immediate deployment is impossible, focusing on long-term response framework.
ASCO 2026 opens 5/29, daraxonrasib pancreatic cancer Phase 3 LBA5 in focus
ASCO 2026 opens 5/29 in Chicago. Revolution Medicines will present metastatic pancreatic cancer RASolute 302 OS unprecedented improvement at 5/31 plenary, Roche giredestrant lidERA 30% recurrence reduction also to be unveiled.
RFK Jr. HHS pushes ACIP appeal, contests 1st court invalidation
After 3/16 federal court invalidated Kennedy's 13 ACIP appointments and Hep B and COVID guideline downgrades, HHS is pursuing appeal at First Circuit. Vaccine policy uncertainty continues through June.
H5N1 California dairy farms infectious virus detected in air and wastewater
5/5 PLOS Biology study confirmed infectious virus in dairy cow breath, milking parlor air, and wastewater of 14 H5N1-positive farms. Many asymptomatic cows tested positive, first field evidence of airborne transmission risk.
WHO declares Bundibugyo Ebola PHEIC; 746 suspected cases, 176 deaths
WHO designated Bundibugyo Ebola in DRC and Uganda as PHEIC on 5/16. As of 5/21: 746 suspected cases, 176 deaths; 85 confirmed cases, 10 confirmed deaths with no approved vaccine or therapy.
FDA approves oral Wegovy: first GLP-1 obesity pill arrives
Novo Nordisk oral semaglutide 25mg received FDA obesity approval. OASIS 4 trial showed average 16.6% weight loss; uninsured launched in US at $149/month.
β¦ RELATED STORYLINELilly orforglipron gets FDA fast-track approval in 50 days
FDA approved Lilly's Foundayo (orforglipron) for obesity on 4/1. Fastest NME approval since 2002 at 50 days from application, with 36mg achieving 11.2% weight loss over 16 months.
β¦ RELATED STORYLINEDOJ appeals RFK Jr ACIP ruling to 1st Circuit
DOJ filed appeal in late April to the First Circuit Court of Appeals against Judge Murphy's 3/16 ruling voiding Secretary Kennedy's 13 ACIP appointments, continuing the vaccine policy overhaul.
H5N1 cumulative human cases pass 1,000; 48% fatality
CDC updated that HPAI A(H5N1) human infections since 1997 across 25 countries crossed 1,000 with ~48% deaths. Q1 2026 added 13 cases including a Bangladeshi pediatric death.
WHO Bundibugyo Ebola PHEIC: 746 suspected, 176 deaths
Bundibugyo Ebola spreading across DRC's Ituri province and Uganda. As of May 21: 746 suspected cases, 176 deaths, 85 confirmed cases, 10 deaths. No Bundibugyo-specific vaccine or treatment exists; 30-50% fatality concerns rising with 6-9 months until clinical trials.
Lilly oral GLP-1 'Foundayo' (orforglipron) FDA obesity approval
First-ever oral GLP-1 taken once daily without food/water restrictions. 72-week 12.4% weight loss exceeded oral semaglutide. With insurance $25/month, cash $149+ β fully opening the pill era.
β¦ RELATED STORYLINEHHS appeals injunction blocking Kennedy vaccine policy
DOJ filed appeal against Judge Murphy's March injunction blocking RFK Jr. vaccine policies including ACIP restructuring. American Academy of Pediatrics and others sued for Administrative Procedure Act violations, with main proceedings expected to be prolonged.
MAHA secures 35% food industry artificial dye phase-out, coalition cracks
Walmart, Hershey, Nestle and 35% of US food industry join artificial dye removal. Child vaccine recommendations cut from 72 doses across 17 diseases to 10. MAHA coalition fractures emerging over glyphosate and vaccine positions.
FDA approves first anal cancer 1L treatment 'retifanlimab' and more oncology wins
PD-1 monoclonal retifanlimab approved as first 1L treatment for advanced anal cancer. Sonrotoclax (relapsed mantle cell lymphoma), atezolizumab (muscle-invasive bladder cancer adjuvant), and first PROTAC based on VERITAC-2 also approved in May β strong oncology month.
WHO declares Congo-Uganda Bundibugyo ebolavirus PHEIC
On May 17 WHO declared Bundibugyo ebolavirus spreading in DRC and Uganda a public health emergency. 600 suspected cases with 139 deaths reported with no vaccine or treatment, leaving containment and supportive care as sole response.
HHS appeals court ruling blocking RFK vaccine policy changes
Health Department appealed Massachusetts federal court ruling blocking RFK's vaccine schedule changes. Fifteen states filed separate lawsuits challenging removal of seven vaccines from HHS recommendations.
Eli Lilly oral GLP-1 Foundayo approved, ushering pill era
Orforglipron (Foundayo) approved for obese and overweight adults. First oral GLP-1 taken without meal restrictions shows weight maintenance post-Ozempic/Zepbound conversion in Phase 3. April launch begins pill era.
β¦ RELATED STORYLINENovo Nordisk oral Wegovy gains EU approval recommendation
On May 22 EMA CHMP recommended EU approval for daily oral semaglutide 25mg. OASIS 4 Phase 3 showed average 16.6% weight loss. US launch saw 1 million patients start in 4 months.
β¦ RELATED STORYLINEFDA pilots AI real-time clinical trial monitoring
FDA launched pilot cloud and AI real-time monitoring of AstraZeneca and Amgen cancer drug trials. Early trial shortening of 20-40% possible with May 29 comment deadline and accelerated drug development ahead.
WHO declares Ebola Bundibugyo PHEIC; 600 suspected cases, 139 deaths
DRC and Uganda Bundibugyo ebolavirus reached 600 suspected cases and 139 deaths by May 20 after WHO's May 17 PHEIC declaration. No approved vaccine or therapeutic available.
Bundibugyo vaccine gap critical; clinical trials require 6-9 months minimum
Approved Ervebo vaccine targets Zaire strain only, proving useless against Bundibugyo variant. Two candidate vaccines exist but clinical entry requires 6-9 months minimum. 25-40% case fatality rate leaves only containment and supportive care.
15 state AGs sue to overturn RFK vaccine recommendation stripping
Connecticut, California and 13 other state attorneys general sued HHS Secretary RFK Jr. to overturn January 5 CDC decision memo removing rotavirus, meningococcal, hepatitis, and coronavirus vaccine recommendations for children.
Eli Lilly oral GLP-1 'Foundayo' FDA approved; pill era begins
Orforglipron (Foundayo) earned FDA approval April 1 as first oral GLP-1 with no food/water restrictions. ATTAIN-1 trial showed 72-week 12.4% weight loss. Launched April 6 via Lilly Direct.
β¦ RELATED STORYLINEGlobal big pharma M&A explodes; Q1 2026 deals hit $84B, double YoY
2026 Q1 biotech M&A surged to $84B from $44.4B YoY. Sun Pharma-Organon $11.75B, Bayer-Perfuse $2.45B lead deals. Full-year 2026 forecast $250B+
WHO Bundibugyo PHEIC official; 8 confirmed, 246 suspected, 80 dead
May 16 declaration. DRC, Uganda spread. 30-50% fatality, no vaccine, no cure.
CDC deploys international team to Uganda, DRC; WHO funding appeal issued
Kampala 2 confirmed reported. Ituri 3 health zones affected. Ghebreyesus May 20 briefing urgent.
15 states sue RFK Jr. to block RSV, hepatitis B, seven-vaccine removal
Connecticut, California lead. HHS appealing ACIP board-block ruling.
Medicare GLP-1 bridge fixed $50 copay July launch; muscle loss warning louder
1-in-8 US adults on GLP-1. Protein, strength training critical. Pricing war ignites.
β¦ RELATED STORYLINEFDA clears Lecanemab home injection; BeiGene sofocrelax MCL approval
Alzheimer's home access expands. BCL-2 market competition intensifies.
Bundibugyo PHEIC widens; 89 deaths tallied
DRC Ituri 9 districts log 10 confirmed, 336 suspected, 88 deaths; Uganda Kampala 2 confirmed, 1 dead. Bundibugyo strain eludes Ervebo, leaving treatment void.
Novo oral Wegovy 1.3M US prescriptions storm
Novo's oral Wegovy hit ~1.3M prescriptions Q1 post-Jan 5 US launch, record GLP-1 launch. Eli Lilly's April oral Foundaeo counterpunch heats duopoly war.
β¦ RELATED STORYLINECDC enhances US entry screening on ebola threat
CDC, DHS May 18 deployed reinforced quarantine, entry bars, health measures for US arrivals. Rapid response teams deployed, safe treatment centers opened, test infrastructure boosted.
RFK Jr. cuts child vaccines 18 to 11; 15 states sue
HHS dropped flu, COVID, rotavirus, hepatitis A/B, meningococcal from recommendations, Denmark-style. 15-state coalition sued; anti-vaccine groups infiltrated ACIP, sparking healthcare pushback.
FDA clears Boxspendi first-in-class aldosterone synthase inhibitor
FDA May 18 approved boxdrostat as first-in-class aldosterone synthase inhibitor for adult hypertension. Resistant hypertension market shifts on novel option.
Novo's Wegovy pill outpaces Lilly's Foundayo in early U.S. rollout
Four months in, oral Wegovy sees tens of thousands of prescriptions via telehealth. Lilly's Foundayo struggles with brand awareness and penetration stateside.
β¦ RELATED STORYLINEArvinas Veppanu wins FDA nod as first PROTAC to market
May 1 approval for protein degrader vepdegestrant targets ESR1-mutant ER+/HER2β advanced breast cancer. Novel modality milestone.
Cytokinetics' aficamten meets Phase 3 goal in non-obstructive HCM
ACACIA-HCM trial success on KCCQ-CSS and peak VO2 (p=0.021, p=0.003). First non-obstructive win challenges BMS Camzyos monopoly.
BeiGene wins accelerated FDA nod for Beqalzi in relapsed MCL
May 13 approval for BCL-2 inhibitor in recurrent/refractory mantle-cell lymphoma. AbbVie Venclexta now faces new competition in hematologic oncology.
Samsung BioLogics added to Dow Jones ESG for fifth year running
May 5 index inclusion after Song-do Plant 5 ramps. CDMO capacity now 845,000L globally; market cap $60 billion puts firm in global biotech top tier.
Eli Lilly's Foundayo breaches 10,000 prescriptions weekly
IQVIA reported 10,248 Foundayo scripts for the week of May 8βup from 7,335 the prior week. Novo's oral Wegovy still leads early.
β¦ RELATED STORYLINEBayer buys Perfuse vision-implant developer for up to $2.45B
Bayer acquired Perfuse Therapeutics and PER-001, an intraocular implant. Deal: $300M upfront plus up to $2.45B in milestones. Targets glaucoma and diabetic retinopathy.
Regenxbio's RGX-202 Phase 3 trial hits primary endpoint
The AFFINITY DUCHENNE study met its primary endpoint on May 14. Two serious adverse events reported; CEO remains confident in FDA approval prospects.
United Therapeutics wins FDA approval for pig-heart clinical trial
United Therapeutics won FDA clearance May 15 to start the UHeart clinical trial for terminal heart failure patients. First formal pig-heart trial enrollment underway.
WHO tracking 13 avian and swine flu cases; no imminent pandemic signal
WHO documented 13 avian and swine influenza cases in Q1 2026, including an H5N1 death in a Bangladeshi child. CDC is monitoring U.S. dairy and poultry workers; public health risk assessed as low.
BeOne Beqalzi earns FDA accelerated approval for MCL; first BCL-2 inhibitor class
Sonrotoclax wins nod for relapsed/refractory mantle cell lymphoma. ORR 52%, response duration 15.8 months. Direct Venclexta challenge emerging.
Isomorphic Labs closes Series B at $2.1B; AlphaFold pipeline expands
DeepMind spinoff banks $2.1B Series B. AlphaFold-driven pipeline advances toward in-house clinical entry readiness.
CDC monitors 41 Americans across 16 states; hantavirus Hondius exposure
Antarctic cruise cluster confirmed 8 cases, 2 probable. U.S. isolation protocol triggers; six-week monitoring window commenced nationwide.
Angelini acquires Catalyst Pharma for $4.1B; enters U.S., expands rare disease
Italian Angelini pays $31.50 per share, $4.1B total. U.S. entry and rare-disease brain-health platform expansion. May's fourth major biotech deal.
Lilly ships Foundayo oral obesity drug; Novo pill competition heats up
Lilly launches three months after Novo oral GLP-1. Foundayo 17% weight loss trails Wegovy pill. Telehealth demand surges.
β¦ RELATED STORYLINEBMS inks $15.2B deal with Hengrui for 13-program oncology, heme, immunology pipeline
BMS fronts $600M, total deal value $15.2B across tumor, hematology, immunology programs. China R&D speed leverage signals big pharma mega-deal renaissance.
Novo oral Wegovy overpowers Lilly's Foundayo 6.7-to-1 in scripts, seizes market
Last week of April: Novo oral semaglutide 135K prescriptions vs Lilly Foundayo 20K. 17% weight loss vs 12% gap hands oral GLP-1 to Novo.
β¦ RELATED STORYLINEMV Hondius cruise Andes hantavirus cluster; five continents on alert
WHO, CDC notified 5/2 of Andes hantavirus clusterβ3 dead, 5 confirmed. Only human-transmissible hantavirus; eight nations launch joint response.
Moleculin MIRACLE AML Phase 2b/3 unblinding imminent; complete remission ~30%
Annamycin plus cytarabine in 45 R/R AML patients hits complete remission ~30% in blinded readoutβexceeds historical benchmark. Results due before 6/30.
Moderna Q1 beats with $389M revenue; flu vaccine PDUFA August 5
Q1 revenue $389M crushes consensus $236M. International revenue recovers to $311M. August 5 PDUFA for flu vaccine marks fifth commercial product milestone.
Lilly GLP-1 US market share tops 60%
Mounjaro and Zepbound combined Q sales $12.8B +56% YoY. Lilly now leads globally including ex-US vs Novo Nordisk.
β¦ RELATED STORYLINEPfizer BRAFTOVI colon cancer 64% response rate
BREAKWATER phase 3 Cohort 3: BRAFTOVI+cetuximab+FOLFIRI in BRAF V600E metastatic colorectal cancer achieved 64% ORR.
FDA Vyvgart seronegative gMG approval timeline set
argenx efgartigimod alfa-fcab PDUFA May 10 date, expands AChR-antibody-negative myasthenia gravis. Home-start option hoped.
Leqembi home-initiation dose FDA decision pending
Eisai-Biogen Leqembi starting dose home-use approval expected May. Alzheimer's access inflection point.
Seaport, Hemab combine $556M IPO, biotech momentum
Two companies debut together on $556M, year-to-date 10 public launches at $3.2Bβbiotech IPO market in recovery.
BMS signs up-to-$15.2B 13-pipeline megadeal with China's Hengrui
Bristol Myers Squibb signed a global licensing and co-development agreement with Hengrui on May 12 covering 13 early-stage oncology, hematology, and immunology programs. The deal includes a $600M upfront payment and up to $950M in near-term payments, with total potential value reaching $15.2B including milestones and royalties. Hengrui's Hong Kong-listed shares jumped more than 13%.
Roche Alzheimer's blood test pTau217 receives European CE mark
Roche announced on May 12 that its Elecsys plasma pTau217 test, co-developed with Eli Lilly, received the European CE mark. Unlike pTau181, it supports not only ruling out Alzheimer's pathology but also confirming it, reducing the burden of invasive CSF testing and brain imaging. CE-market launch is planned for July 2026.
Eli Lilly overtakes Novo Nordisk in ex-U.S. GLP-1 share
Q1 overseas Mounjaro revenue reached $8.7B, beating consensus and allowing Eli Lilly to overtake Novo Nordisk in non-U.S. GLP-1 market share for the first time. In oral GLP-1s, however, Novo's Wegovy pill launched first in January and appears to be seeing faster early uptake than Lilly's Foundayo, or orforglipron, launched in April.
β¦ RELATED STORYLINETrump administration MFN drug-pricing policy reaches voluntary deals with 17 pharma firms
The White House said in May 12 materials that its most-favored-nation drug-pricing policy has secured voluntary agreements with 17 global pharmaceutical companies and would save federal and state Medicaid programs $64.3B over ten years. Industry resistance continues, however, with list prices for 872 branded drugs rising a median 4% so far in 2026.
Rare-disease pipelines advance at AskBio and BridgeBio; telehealth Hims misses
AskBio dosed the first patient in a phase 1/2 gene-therapy trial for late-onset Pompe disease, while BridgeBio filed an FDA new-drug application for encaleret in autosomal dominant hypocalcemia type 1. Meanwhile, as telehealth competition in compounded GLP-1s intensified, Hims & Hers reported quarterly revenue below consensus on May 12 and shares weakened.
MV Hondius: 94 evacuated, WHO reassures
The Dutch cruise ship MV Hondius, carrying Andes hantavirus cases, docked in Canary Islands on May 10, disembarking 94 passengers from 19 countries. Three died, seven confirmed, nine suspected. Human-to-human transmission confirmed in some cases, but WHO Director Tedros said general public risk is low.
VYVGART PDUFA May 10; Intellia CRISPR shows gains
argenx VYVGART (efgartigimod) for seronegative generalized myasthenia hits May 10 PDUFA. Intellia's lonvo-z for hereditary angioedema showed 87% attack-rate cut vs. placebo in phase 3, with 60% remaining attack-free (vs. 11% placebo), signaling the first in vivo CRISPR path to approval.
Foundayo vs. Wegovy: GLP-1 oral duel
Lilly's oral Foundayo (orforglipron) saw 20,000+ patients begin dosing post-launch, 1,000 new scripts per day, 80% new-to-GLP1. Novo's Wegovy pill leads with tens of thousands on board in four months. Novo holds 2026 revenue/profit guidance at -5% to -13%.
β¦ RELATED STORYLINEH5N1 case in Bangladesh child; U.S. vigilant
WHO Q1 2026 report logged 13 zoonotic flu human infections including one Bangladesh child H5N1 death (unreported earlier). U.S. dairy and poultry worker exposures remain sporadic; no sustained human-to-human spread. CDC rates public risk 'low'.
Korean biosimilars' golden decade
Samsung Bioepis' Pyzchiva (Stelara equivalent) cracked U.S. top-3 ustekinumab market in one year. Celltrion's Steqeyma gains via Costco. Global pharma M&A races to bag biosimilar firms ahead of blockbuster patent cliffs.
MV Hondius hantavirus: 8 cases, 3 deaths, expanding response
WHO tallied eight Andes hantavirus (ANDV) cases, three deaths (38% fatality rate), and six lab confirmations as of May 8 aboard MV Hondius. The ship docked in Tenerife early May 10; 17 Americans were transferred to Nebraska's national quarantine facility. WHO assessed global risk as low while Argentina expedited 2,500 diagnostic kits to five nations.
Aficamten clears non-obstructive HCM trial, opening billions
Cytokinetics unveiled May 5 that aficamten (Myqorzo) hit its primary endpoint in ACACIA-HCM, a phase 3 trial in non-obstructive hypertrophic cardiomyopathy. This is territory BMS's Camzyos never entered, opening a multibillion-dollar market. Analysts call it 2026's top cardiovascular catalyst.
Daraxonrasib doubles pancreatic-cancer survival
Revolution Medicines' pan-RAS inhibitor daraxonrasib nearly doubled overall survival in metastatic pancreatic adenocarcinoma: 13.2 months combined versus 6.7 months chemotherapy alone in phase 3. FDA granted fast-track and expanded-access approval. Analysts view this as the inflection point for the first RAS inhibitor to reshape treatment standards.
Vyvgart expands to all myasthenia gravis serum types
Argenx won FDA approval May 8 for Vyvgart and Vyvgart Hytrulo to treat all adult generalized myasthenia gravis serum typesβAChR-positive, MuSK, LRP4, and seronegative. The label expansion broadens eligible patient populations significantly. PDUFA date was May 10.
Survodutide achieves 16.6% weight loss over 76 weeks
Boehringer Ingelheim and Xyvea's dual GLP-1/glucagon agonist survodutide showed 16.6% weight reduction in 76-week phase 3, data locked April. NIH separately published how oral small-molecule GLP-1s penetrate deep brain reward circuits to suppress appetite. Medicare begins $50/month GLP-1 options in July.
β¦ RELATED STORYLINEBiotech M&A blitz: seven deals in one week
BioCentury tallied seven biotech M&A announcements in early Mayβthree exceeding $1B. H1 2026 reached 19 deals; CareDx acquired liquid-biopsy firm Naveris as the sole US buyer. Momentum accelerates post-Q1's record $15.6B deal volume.
MV Hondius Hantavirus: 3 Deaths, 6 Confirmed as Ship Reaches Tenerife
WHO confirmed 6 of 8 suspected cases with 3 deaths (2 confirmed Andes variant) as of May 9. Over 100 passengers, including 17 Americans, began disembarkation in the Canary Islands with U.S. and UK deploying evacuation aircraft.
β¦ RELATED STORYLINEViridian Elegrobart Phase 3 REVEAL-2 Achieves 50% PRR in Chronic Thyroid Eye Disease
May 5 Phase 3 REVEAL-2 data showed 50% partial response rate (versus 15% placebo) for four-weekly elegrobart dosing, with eight-weekly achieving 54%, securing Q1 2027 BLA filing pathway.
CMS Launches July 2026 Medicare GLP-1 Obesity Pilot
May 6 CMS announced GLP-1 bridge model (July 2026βDecember 2027) offering discount coverage for Wegovy, Zepbound KwikPen, Foundayo tablets for Medicare enrollees with BMI 27+ (with comorbidities) or BMI 35+.
β¦ RELATED STORYLINEArvinas Veppanu Becomes First PROTAC FDA Approval for ESR1-Mutant Breast Cancer
May 1 FDA approval of Arvinas' vepdegestrant (Veppanu) for ER+/HER2β/ESR1-mutant advanced/metastatic breast cancer marks first commercial PROTAC (heterobifunctional protein degrader) success.
Capricor Deramiocel Phase 3 HOPE-3 Meets Primary in Duchenne Muscular Dystrophy
Phase 3 HOPE-3 met PUL v2.0 primary endpoint, with reduced cardiac LGE progression (p=0.022) and improved LVEF (p=0.017). PDUFA date set for August 22, 2026.
β¦ RELATED STORYLINELilly Foundayo (orforglipron) Approved as First Non-Peptide GLP-1 Weight-Loss Pill
FDA approved Lilly's Foundayo on 4/1 for chronic weight management. As the first non-peptide GLP-1 receptor agonist oral formulation, it eliminates meal and water restrictions. CNPV priority review determined the action in 50 days.
β¦ RELATED STORYLINEVeppanu (vepdegestrant) Approved for ER+/HER2- Metastatic Breast Cancer
FDA approved Veppanu on 5/1 for advanced and metastatic ER+/HER2- breast cancer with ESR1 mutations. This marks the first success of the heterobifunctional protein degradation class.
Novo Nordisk Wegovy Oral Formulation; First GLP-1 Weight-Loss Tablet
FDA approved Novo Nordisk's Wegovy oral tablet as the first GLP-1 medication in pill form for weight loss. Tablet availability reduces patient reluctance versus injection therapy, accelerating market expansion.
β¦ RELATED STORYLINENuvation Bio Files IBTROZI sNDA for ROS1-Positive NSCLC
Nuvation Bio submitted a supplemental NDA on 5/6 for IBTROZI (taletrectinib) in advanced ROS1-positive NSCLC. Target action date: January 4, 2027.
FDA Authorizes Four Glas E-Cigarette Products; Total Approved ENDS Reaches 45
On 5/5, FDA approved four Glas electronic nicotine delivery system products through the PMTA pathway, bringing total authorized ENDS products to 45. The decision introduces new policy inflection in tobacco regulation.
β¦ RELATED STORYLINECMS Launches BALANCE Model for Medicaid GLP-1 Weight Management; Coverage Begins in May
The BALANCE model provides free GLP-1 therapy paired with lifestyle support programs, expanding Medicaid access to obesity treatment.
β¦ RELATED STORYLINEGLP-1 Users Face Greater Social Stigma Than Diet-Adherent Peers; Rice Study
A new Rice University study finds that individuals losing weight via GLP-1 face more negative social perception than those employing diet and exercise, or even individuals with untreated obesity, highlighting emerging social acceptance barriers.
WHO Guidelines Endorse GLP-1 Use for Adult Obesity Treatment
The World Health Organization's guidance published in JAMA establishes GLP-1 as standard-of-care therapy for eligible adults with obesity.
β¦ RELATED STORYLINEDiaMedica Updates Pipeline on May 7; Preeclampsia, Stroke Programs Featured
DiaMedica Therapeutics presented Q1 results and pipeline updates for preeclampsia, fetal growth restriction, and acute ischemic stroke candidates.
Vepdegestrant Approved May 1 for ER+/HER2- Advanced Breast Cancer
The FDA approved vepdegestrant as a targeted hormone therapy option, expanding the treatment arsenal for hormone receptor-positive breast cancer.
β¦ RELATED STORYLINEVeppanu FDA Approved; First-in-Class Protein Degrader for Breast Cancer
On May 1, FDA approved Veppanu for ER+/HER2-/ESR1-mutant advanced breast cancer. Protein degradation mechanism is key.
β¦ RELATED STORYLINENuvation Bio's IBTROZI sNDA Filed with FDA on May 6
Supplemental NDA for IBTROZI, for ROS1-positive advanced non-small cell lung cancer, submitted to FDA.
GLP-1 Associated with Reduced Depression, Anxiety, and Addiction Risk
Large cohort data show reduced depression, anxiety, and psychiatric hospitalization rates in semaglutide and other GLP-1 users.
β¦ RELATED STORYLINERice Study: GLP-1 Users Experience Greater Social Stigma Than Diet/Exercise Weight Loss
Research finds GLP-1 users report greater social stigma compared to those losing weight through diet and exercise, prompting policy discussions.
CMS BALANCE Model: Medicaid GLP-1 Coverage Begins May; Medicare Part D Follows July
Under the voluntary BALANCE model, Medicaid GLP-1 obesity treatment coverage launches May, with Medicare Part D coverage beginning July.
β¦ RELATED STORYLINEPfizer Q1 revenue $14.45B, +5% YoY
EPS $0.75 exceeds consensus $0.72; 2026 revenue guidance $59.5-62.5B reconfirmed.
β¦ RELATED STORYLINEVeppanu (vepdegestrant) first PROTAC FDA approval
Arvinas and Pfizer for ER+/HER2-/ESR1 mutation advanced breast cancer.
Yale-led breast cancer treatment technology receives first FDA approval
Yale-led technology receives first-ever FDA approval on May 7.
β¦ RELATED STORYLINEVYVGART antibody-negative indication PDUFA 5/10
Decision imminent for AChR antibody-negative patients.
β¦ RELATED STORYLINELEQEMBI IQLIK weekly loading dose PDUFA 5/24
Eisai and Biogen Alzheimer's early treatment decision pending.
MV Hondius Hantavirus: 3 Deaths, 5 Confirmed Cases as of May 6
As of May 6, the MV Hondius hantavirus outbreak has resulted in 3 deaths and 5 confirmed cases, with co-monitoring by WHO and CDC.
Twelve Countries Implement Passenger Tracking and Observation
Canada, Germany, the Netherlands, Singapore, the United Kingdom, the United States, Switzerland, and eight other nations are actively monitoring disembarked passengers.
Five U.S. States Launch Passenger Monitoring Programs
Five U.S. states have initiated monitoring protocols for individuals who entered the country after disembarking from MV Hondius.
Global Wellness Summit Identifies Ovarian Aging Arrest as Next-Generation Biotech Keyword
The Global Wellness Summit has designated ovarian stem cell therapy and targeted ovarian fibrosis treatment as core health trends for 2026.
End of Anti-Aging Era: 'Skin Longevity' Framework Emerges
The traditional anti-aging paradigm is shifting toward 'skin longevity,' combining biotech, AI diagnostics, and novel active ingredients in integrated care regimens.
Veppanu Approved for ER+ Breast Cancer
On May 1st, the FDA approved Veppanu (bepedegertrant) for advanced and metastatic ER+/HER2- breast cancer with ESR1 mutations.
First Non-Psychiatric Dementia Agitation Treatment Approved
On April 30th, the FDA cleared the first non-psychiatric class medication for agitation associated with dementia, reducing elderly psychiatric care burden.
Idvynso HIV Treatment Approved April 21st
The doravirine and islatravir combination Idvynso gained approval as an adult HIV-1 treatment, offering a once-daily alternative to existing antiretroviral therapies.
GLP-1 Reduces Psychiatric Hospitalization and Sick Leave by 42%
A 10-year longitudinal study of approximately 100,000 patients showed semaglutide reduced psychiatric hospitalizations and sick leave by 42%, depression risk by 44%, and anxiety by 38%.
Rybelsus Oral GLP-1 Launches in U.S. Starting May 4th
Novo Nordisk began full commercial distribution of oral Rybelsus in the U.S. on May 4th, reducing injection-related barriers and expanding the GLP-1 tablet market.
FDA Approves AUVELITY for Alzheimer's Agitation on April 30
AXS-05 (bupropion/dextromethorphan) approved for Alzheimer's dementia-related agitation indication.
FDA Approves Interchangeable Insulin Glargine 'Langlara' on April 29
Lantus biosimilar approved for diabetes treatment with interchangeable designation.
FDA Advisory Panel Reviews Camizestrant and Truqap on April 30
Proceedings for ER+/HER2- early breast cancer and PTEN-deficient metastatic hormone-sensitive prostate cancer underway.
Medicare GLP-1 Bridge Program Launch Set for July 1
Monthly $50 copay guarantee for obesity medications; pilot runs July 1 through December. Millions of beneficiaries expected to benefit.
NIH Clarifies Oral GLP-1 Small-Molecule Mechanism in Reward Circuitry
Orforglipron and similar compounds modulate brain reward pathways to suppress hedonic appetite, offering non-injectable, cost-effective advantages.
FDA Proposes Excluding GLP-1 from 503B Bulk Drugs (April 30)
Semaglutide, tirzepatide, and liraglutide removed from 503B bulk drug list proposal, signaling compounding era conclusion.
Medicare GLP-1 Bridge Program Launches July 1
$50 monthly copay benefit for Foundayo, Wegovy, and Zepbound KwikPen through December 31, 2027.
Medicaid GLP-1 Coverage Reductions Expanding
California, New Hampshire, Pennsylvania, and South Carolina reductions followed by Massachusetts and Rhode Island review proceedings.
GLP-1 Indication Expansion: Atrial Fibrillation, Alcohol Disorder, Depression, Diabetic Retinopathy
April clinical data releases documented efficacy beyond obesity across four additional therapeutic domains, initiating multi-indication era.
UCSF GLP-1 Synaptic Plasticity Research
GLP-1 may influence brain neural circuit rewiring, accelerating Alzheimer's and cognitive function drug candidate pipelines.
April 2026 Β· 150
FDA Approves Langlara (Insulin Glargine-aldy) as Lantus Interchangeable Biosimilar
Sanofi's insulin glargine-aldy (Langlara) approved April 29 as interchangeable Lantus biosimilar. Expands insulin options and reduces patient burden.
Gilead's Once-Daily HIV Therapy Granted Priority Review
Bictegravir plus lenacapavir once-daily NDA received priority review April 29. Potential paradigm shift toward simplified once-daily oral HIV management.
BeOne TEVIMBRA Wins Priority Review for HER2+ Gastric/Esophageal Cancer
BeOne Medicines' TEVIMBRA granted priority review for first-line HER2+ gastroesophageal adenocarcinoma. Expands immunotherapy first-line options.
Lilly Foundayo Launches at $149 Self-Pay, $25 Insured; Competes with Novo Wegovy Tablet
Oral GLP-1 Foundayo, approved in early April, launched via LillyDirect, pharmacies, and telehealth. Pricing: $149/month lowest dose self-pay, $25 commercial insurance. Competes against Novo Nordisk Wegovy tablet (600K March prescriptions).
Novo Nordisk Wegovy Tablet Hits 600K March Prescriptions; First-Mover Advantage
Novo Nordisk Wegovy oral formulation surpassed 600K prescriptions in March, ~3 months ahead of Lilly Foundayo launch. Price and access competition intensifying.
FDA Approves Langlara Insulin Glargine Biosimilar
On April 29, the FDA approved insulin glargine-aldy (Langlara), a Lantus-compatible biosimilar for long-acting insulin treatment of diabetes.
FDA Proposes Restricting Compounding of GLP-1 Active Ingredients
On April 30, the FDA proposed limiting outsourced facility bulk compounding of semaglutide, tirzepatide, and related GLP-1 compounds, targeting illicit market channels.
Gilead's Bictegravir-Lenacapavir Once-Daily HIV Regimen Granted Priority Review
Gilead's bictegravir-lenacapavir once-daily HIV therapeutic regimen has been designated for FDA priority review, signaling simplified treatment option expansion.
Eli Lilly's Oral GLP-1 Candidate Orforglipron Advances in Approval Pathway
Eli Lilly's oral GLP-1 compound orforglipron is advancing toward regulatory approval, positioning itself as a potential advantage over Novo Nordisk's oral semaglutide (Rybelsus).
Jaguar Health's Crofelemer Demonstrates Efficacy in Cancer Drug-Induced Diarrhea Trial
On April 29, Jaguar Health announced statistically significant efficacy of Canalevia-CA1 (crofelemer) in treating chemotherapy-induced diarrhea.
FDA Approves Daraxonrasib Expanded Access in Two Days β 60% Mortality Reduction in Pancreatic Cancer
Revolution Medicines submitted 4/28; FDA approved 4/30. Based on clinical data showing 60% mortality risk reduction versus chemotherapy in previously treated metastatic PDAC.
Scancell iSCIB1+ Receives Fast Track 4/28 β Advanced Melanoma
iSCIB1+ immunotherapy granted fast-track designation for advanced melanoma treatment. Follows Opna OPN-6602 (multiple myeloma) April 15 and NextCure SIM0505 (ovarian cancer) April 7 fast tracks.
Lilly Foundayo (Orforglipron) Approved April 1 β Oral GLP-1
Once-daily GLP-1 tablet: $25 monthly with insurance; $149β349 self-pay. Medicare starts summer at $50. Direct competition with Novo Wegovy pill (600,000 prescriptions in March).
FDA Otarmeni Accelerated Approval 4/23 β OTOF Genetic Hearing Loss Gene Therapy
AAV vector-based lunsotogene parvec-cwha. Approvals same period: 4/21 Idvynso (HIV-1); 4/29 Langlara (insulin glargine biosimilar).
Tecartus (Brexu-cel) Full Approval β Relapsed/Refractory MCL
FDA converted accelerated approval to standard approval. Long-term follow-up data supports durability. ADC 'I-DXd' receives priority review for advanced SCLC.
FDA Approves Lilly's Foundayo (Orforglipron)
Eli Lilly's once-daily oral GLP-1 Foundayo received FDA approval. It is the first oral GLP-1 requiring no dietary restrictions.
ATTAIN-1 Phase 3: Up to 12-Pound Weight Loss at Highest Dose
ATTAIN-1 Phase 3 results showed 12-pound average weight loss (12.4%) at the highest dose, compared to 16.6% with oral semaglutide.
Obesity Surpasses Oncology as Top Late-Stage Therapy
For the first time in 16 years, obesity treatment leads the late-stage pipeline value hierarchy. Obesity and diabetes now comprise 38% of late-stage pipeline commercial value.
Novel Approaches Beyond GLP-1 Target Emerging
Research published April 16 suggests emerging pharmacology approaches that bypass the GLP-1 target, challenging conventional obesity treatment paradigms.
Less Than 10% of Eligible Patients Use GLP-1
GLP-1 penetration among eligible patients remains below 10%, leaving significant room for multiple market participants.
AUVELITY Alzheimer's Agitation Indication Decision Due April 30
Axsome's AUVELITY faces FDA decision on April 30 for Alzheimer's-associated agitation indication. Approval would position it as a first-line oral option.
Wegovy Oral GLP-1 Approved; First Obesity Oral Medication
The FDA approved Novo Nordisk's Wegovy oral GLP-1 for obesity indication, marking the first oral GLP-1 for weight loss. Full U.S. market entry began in January, signaling a price decline and oral medication expansion cycle in 2026.
Beyond GLP-1: GIP and Glucagon Dual-Pathway Medications Emerge
STAT reported emergence of a new drug class targeting GIP and glucagon receptors, rather than GLP-1 itself, to reduce nausea side effects. Expansion across multiple disease indications is key.
FDA Posts April 27 Notice; May 28 VRBPAC Meeting on 2026-2027 COVID Vaccines
The FDA posted a Federal Register notice on April 27 announcing a May 28 Vaccines and Related Biological Products Advisory Committee meeting to discuss 2026-2027 COVID-19 vaccine composition.
FDA Direct-to-Consumer Conference Convenes in Boston
On April 21, FDA officials, industry representatives, and academics gathered in Boston for the DTC National Conference to discuss direct-to-consumer advertising and patient access issues.
Stanford's BRP Molecule β 'Natural Ozempic' Discovered via AI
Suppresses appetite and reduces body fat without nausea or muscle loss; preclinical stage.
GLP-1 Resistance β Approximately 10% Have Genetic Non-Response
Stanford researchers clarify mechanism of Ozempic and Wegovy non-responders.
Survodutide Phase 3 β Average 16.6% Weight Loss
76-week trial shows overwhelming efficacy vs placebo (3.2%).
Down Syndrome CRISPR β Chromosome 21 Overexpression 'Silenced'
Preclinical results promising; announced April 24.
GLP-1 'Target-Switching' Hypothesis β GIP/Glucagon Pathway
Original researchers propose novel approach; potential to bypass side effects.
Eli Lilly's Orforglipron (Foundayo) Gains FDA Approval
72-week average weight loss: 12% vs. 0.9% placebo. First GLP-1 tablet without meal restrictions.
Eli Lilly Acquires Kelonia Therapeutics
Secures cancer-targeting gene therapy pipeline; deal announced April 24.
Foundayo Self-Pay Pricing Starts at $149/Month
Commercial insurance: $25/month. Medicare copay capped at $50 effective July 1.
FDA Moves to End GLP-1 Compounded Pharmacy Products
FDA negates clinical necessity; begins rulemaking to shut down compounded product sales channels.
Next-Generation GLP-1 Candidates Target Expanded Pathways
New drug candidates beyond GLP-1 targeting neurological and metabolic pathways emerging.
FDA Approves HIV-1 Treatment Idvynso on April 21
The FDA approved Idvynso (doravirine/islatravir combination) on April 21 for the treatment of adult HIV-1 infection.
Genetic Hearing Loss Gene Therapy Otarmeni Receives Accelerated Approval on April 23
Lunsotogene parvec-cwha (Otarmeni) received accelerated approval on April 23, marking the first gene therapy for inherited hearing loss.
Novo Nordisk Wegovy Oral Formulation Enters GLP-1 Pill Market
Novo Nordisk's Wegovy oral formulation gained market entry, with a starting dose of 1.5mg available at $149 monthly through pharmacies and telehealth channels.
Eli Lilly Foundayo Launches Three Months Behind Novo Nordisk
Eli Lilly's Foundayo entered the market three months after its competitor but is projected to capture 60% of the daily oral market by 2030.
Lantus Interchangeable Biosimilar Langlara Approved April 29
Insulin glargine-aldy (Langlara) received approval on April 29 as an interchangeable biosimilar to Lantus, adding pricing pressure to diabetes care.
Wegovy and Zepbound Each Lose Coverage for 12 Million
88% of remaining enrollees subject to prior authorization or BMI restrictions.
Eli Lilly Launches Foundayo (Orforglipron)
First small-molecule GLP-1 oral agent; 11% weight loss in clinical trials.
Wegovy Oral Formulation Expands Commercial Availability
Novo Nordisk begins pharmacy distribution nationwide.
Non-GLP-1 Obesity Hypothesis; GIP and Glucagon Targeting
Original researchers propose novel hypothesis: GLP-1 targeting unnecessary.
152 Million Americans Reside in Failing Air Quality Counties
Earth Day report highlights respiratory and cardiovascular risks.
GLP Diet app launches April 21; exceeds 2,500 reviews
Custom nutrition, 5-minute workouts, and progress tracking integrated for Ozempic and Mounjaro users officially launched.
Tom Brady, eMed partner to offer GLP-1 to healthcare workers at $25/month
Fixed employer cost of $25 per employee; employee copay $99 for GLP-1 solution.
GLP-1 indication broadens to atrial fibrillation, depression, diabetic retinopathy
April clinical updates hint at GLP-1 efficacy expansion to alcohol use disorder, depression, and diabetic retinopathy.
Stanford study: 10% of patients show GLP-1 resistance
One in ten patients on GLP-1 diabetes medications may experience diminished response. Next-generation targets needed.
NIH: oral small-molecule GLP-1 penetrates brain; suppresses cravings
Oral small-molecule GLP-1 drugs cross the blood-brain barrier to inhibit cravings, representing a next-generation obesity pharmacology candidate.
GLP-1 Oral Formulation Prescribed to 170K Patients in Six Weeks
The adoption curve for orals is outpacing injectables' initial trajectory, marking a paradigm shift in obesity treatment delivery.
Up to 40% of Weight Loss Attributable to Lean Muscle Depletion
Skeletal muscle loss accompanies 'Ozempic face' concerns, positioning muscle-preserving therapeutics as the next-generation priority.
FDA Approves Idvynso for Adult HIV-1 Infection on April 21
The fixed-dose combination of doravirine and islatravir expands antiretroviral options.
Otarmeni Receives Accelerated Approval for Hereditary Hearing Loss on April 23
FDA expedited lunsotogene parvec-cwha approval, broadening the gene-therapy footprint in rare diseases.
GLP-1 Drug Cycling Becomes Widespread Practice
Users frequently stop and restart medication; long-term cycling safety data remains scarce.
Eli Lilly's Foundayo Achieves Broad U.S. Distribution Post-FDA Approval (April 1)
Following April 1 FDA accelerated approval, Eli Lilly's Foundayo (orforglipron) began LillyDirect shipments April 6, then expanded to wide pharmacy and telehealth networks mid-April. It is the first oral GLP-1 formulation unrestricted by meal, water or timing.
UnitedHealth Raises 2026 Full-Year Guidance on Strong Q1 Performance
UnitedHealth posted Q1 revenue of $111.72B and adjusted EPS of $7.23, raising 2026 guidance from $17.75 to $18.25+. Medical benefit ratio of 83.9% beat consensus of 85.5%.
CMS Finalizes GLP-1 Bridge Program; Medicare 'GLP-1 Era' Begins July 1
CMS codified eligibility and Part D participation for the GLP-1 Bridge Program in April, with the demonstration running July 1, 2026βDecember 31, 2027. A temporary Medicare GLP-1 coverage bridge precedes the permanent BALANCE model launch.
FDA Generic Drug Review Times Accelerate; ANDA Approvals Faster
FDA generic drugs program monthly and quarterly activity reports released April 17 showed ANDA average approval time dropping from 35.93 months in Q1 to 32.82 months in Q2; median fell from 25.65 to 20.29 months. April saw 17 first-cycle approvals.
GLP-1 'Ozempic Personality' Side Effect Emerges Clinically; Cycling Safety Unclear
Washington Times (April 30) and NPR (April 15) reported GLP-1 patients experiencing appetite, libido and social engagement declineβtermed 'Ozempic personality'βwith some cycling drug use on and off. Long-term safety and effects of cycling remain understudied.
Lilly Foundayo (GLP-1 Pill) FDA Approval (April 1)βShipped in April
Once-daily GLP-1 pill Foundayo approved. 72-week trial highest-dose group: 12% weight loss. Medicare $50/month; insured $25 coupon; uninsured $149β349.
Idvynso (HIV Combination) Approved April 21
FDA approved Idvynso for adult HIV-1βcombining doravirine and islatravir as a novel antiretroviral regimen.
OtarmeniβGene Therapy for Hereditary Hearing Loss (Accelerated Approval, April 23)
AAV-based gene therapy Otarmeni received accelerated approval for OTOF-mediated hereditary hearing lossβlandmark for genetic hearing treatments.
Novo's Wegovy Pill Surpasses 600,000 Prescriptions in March
Wegovy oral formulation exceeded 600,000 prescriptions in March alone, outpacing initial forecasts and signaling fierce direct competition with Lilly's Foundayo.
STAT: Beyond GLP-1βNext-Generation Obesity Drug Research Accelerates (April 16)
STAT reports April 16 that developers are actively exploring non-GLP-1 targets to sidestep adverse effects and resistance. New paradigm emerging.
Eli Lilly's Foundayo gains FDA approval and hits market by April 6
Foundayo (orforglipron) received FDA approval on April 1 using the agency's new commissioner voucher program for expedited review. Insurance coverage costs $25/month; self-pay is $149. No meal restrictions required.
Novo's Wegovy pill posts record first-quarter launches; 600,000+ prescriptions
Wegovy's pill formulation set the all-time obesity-treatment launch record. Over 600,000 prescriptions were written in the first quarter. The downside: fasting and a 30-minute wait period are required.
FDA approves Regeneron's Otarmeni (AAV gene therapy for hearing loss)
Regeneron's Otarmeni gained accelerated approval on April 23 for OTOF-related hearing loss. Additional April approvals include Idvynso (HIV-1, 4/21) and Langlara, a Lantus biosimilar (4/29).
Caltech releases CellSAM for automated single-cell identification
Caltech researchers unveiled CellSAM, an AI tool for automatically identifying and segmenting individual cells across optical, fluorescence, and electron microscopy images.
Health insurance burden climbs: family premiums up 23% in five years
Workers' family insurance premiums average $6,900 after a 23% five-year increase. Two-thirds of Americans cite health-cost anxiety. Prior authorization and billing complexity add patient-safety risks.
FDA Approves Eli Lilly's Foundayo as First GLP-1 Obesity Pill
The FDA approved Eli Lilly's orforglipron (Foundayo) on April 1 as the first GLP-1 oral obesity treatment requiring no timing restrictions around food or water.
Stanford Researchers Identify 'Natural Ozempic' Molecule
Stanford researchers identified a BRP molecule that acts on appetite centers without nausea or muscle loss, dubbing it a 'natural Ozempic.' Preclinical data showed diet and body fat reductions.
New Study Flags GLP-1 Resistance in Roughly 10% of Patients
Researchers identified a genetic variant causing GLP-1 resistance in approximately 10% of patients, offering insight into disparities in drug response.
GLP-1 Users Increasingly Stop and Restart Medications Despite Medical Caution
NPR documented a rising trend of patients discontinuing and restarting GLP-1 drugs like Wegovy and Zepbound, a practice clinicians discourage but which occurs frequently in practice.
Novo Nordisk's Wegovy Captures 65% Share of New GLP-1 Prescriptions
Novo Nordisk's Wegovy commands 65% of new GLP-1 obesity drug prescriptions in the United States, extending market dominance.
Foundayo Opens GLP-1 Oral Obesity Treatment Market
Eli Lilly's Foundayo received FDA approval April 1, with cash pricing set at $149 monthly (matching oral Wegovy) and Medicare coverage starting summer at $50 monthly. Projected 2030 sales of $14.8 billion.
Utah Measles Climb to 602 Cases; U.S. Reaches 1,487
Utah has accumulated 602 measles cases with 1,487 nationally confirmed. Twenty-four new cases emerged in 2026, with 93% tied to cluster transmission. The outbreak threatens the U.S. measles elimination status.
Colorado and Pennsylvania Accelerate Avian Flu Culling
Weld County, Colorado culled 1.3 million layers; Lancaster County, Pennsylvania eliminated 720,000 layers. Over 30 days, 59 farms were affected, with 4.9 million birds culled.
FDA Proposes Excluding GLP-1 from Compounding List
The FDA proposed April 30 to exclude Novo Nordisk and Eli Lilly obesity and diabetes active pharmaceutical ingredients from the compounding allowance list, citing lack of clinical need for compounded GLP-1 products.
Late-April FDA Approvals Include HIV and Genetic Therapies
April 21: Idvynso (doravirine/islatravir) HIV-1 approval. April 23: Otarmeni accelerated approval for hereditary OTOF deafness gene therapy. April 29: Langlara (insulin glargine biosimilar) approval.
AstraZeneca Expands Tezspire Asthma Label
On April 13, the FDA granted AstraZeneca's asthma drug Tezspire (tezepelumab-ekko) expanded approval, broadening its indicated uses.
FDA Orders Eli Lilly to Submit Additional Safety Data for Foundayo
Released April 14, FDA approval documents require Eli Lilly to submit further cardiovascular and hepatic safety data on Foundayo (orforglipron). The rapid approval carried the Commissioner's National Priority Voucher.
Medicare GLP-1 Copay Cap at $50 Expands Senior Access
Medicare's GLP-1 benefits program capped out-of-pocket costs at $50 monthly, accelerating both price compression and senior adoption.
Trump Signs Psychedelic Mental Health Executive Order
The Trump administration signed an executive order in April to expedite psychedelic drug research and access for mental health, with veterans prioritized.
Neomorph's $100M Series B Funds NEO-811 Clinical Advancement
The $100 million Series B accelerates NEO-811's Phase 1/2 trials in renal cell carcinoma, setting the stage for near-term readouts.
Stanford "Natural Ozempic": AI peptide BRP
No nausea, no muscle wasting. Appetite suppression in preclinical models. Science Daily, 4/12.
GLP-1 resistance found in 10% of patients
Genome Medicine, 3/29: certain mutations blunt drug response. Precision dosing essential.
Renaissance Pharma daretabart FDA Fast Track for high-risk neuroblastoma
Anti-GD2 antibody. 4/14 announcement. Oncology momentum 4/13β15 window.
AstraZeneca Tezspire monograph updated 4/13
Tezepelumab-ekko expanded guidance. Eosinophilic asthma and general asthma standard-of-care signals shift.
Celltrion ADC CT-P71 Fast Track (4/9)
Nectin-4-targeting antibody-drug conjugate for advanced metastatic urothelial cancer. Korean ADC export accelerates.
Foundayo Oral GLP-1 FDA Approval (April 1)
FDA approved Foundayo for obese and overweight adultsβthe first oral GLP-1 receptor agonist requiring no food/water constraints before dosing.
Retatrutide -28.7% Weight Loss, -75.8% Pain
In obese adults with knee osteoarthritis, Retatrutide delivered mean -28.7% weight loss and WOMAC pain reduction of -75.8%. Regulatory submission expected in 2026.
AI Mental-Health Apps Clinically Validated
Flourish demonstrated efficacy in two large RCTs. Headspace's Ebb, Woebot, Wysa, and Ash entering mainstream clinical adoption.
AI Integration in Mental-Health Workforce: Mixed Sentiment
NPR April 7 report: mental-health professionals simultaneously embrace and fear AI adoption. Clinical safety and validation gaps persist.
Claude's Internal Emotion Vectors Identified
Mechanistic interpretability research publicly identified internal emotion vectors activating across human emotional contexts in Claude models.
AbbVie ELAHERE Plus Carboplatin: 62.7% Phase 2 ORR
At SGO 2026 (April 10β13, San Juan), AbbVie presented Phase 2 data (IMGN853-0420) showing mirvetuximab plus carboplatin achieved a 62.7% objective response rate in platinum-sensitive ovarian cancer.
Lilly's Foundayo (Oral GLP-1) Earns FDA Approval April 1
Foundayo, an oral GLP-1, received FDA approval on April 1 based on ATTAIN-1 (non-diabetic obesity/overweight) and ATTAIN-2 (diabetes plus obesity) data. Maximum-dose mean weight loss was 27.3 lbs (12.4%).
Daraxonrasib Doubles One-Year Pancreatic Cancer Survival
The RAS(ON) inhibitor daraxonrasib achieved roughly double the one-year survival rate in advanced pancreatic cancer Phase 1/2 dataβmajor oncology news dominating mid-April coverage (Northwestern, NatGeo, Dana-Farber).
FDA Grants Fast Track to Multiple Oncology Candidates in April
The FDA designated fast-track status to multiple oncology programs in April, spanning ovarian, bladder, and pancreatic indications, including PAS-004 (NF1 pathway).
FDA Launches 'Real-Time' Clinical Trials Pilot
STAT reports the FDA is piloting 'real-time clinical trials' with AstraZeneca, Amgen, and others to accelerate drug development, with oncology as the priority domain.
Foundayo oral GLP-1 starts free shipping via LillyDirect (April 6)
FDA-approved April 1; first GLP-1 pill with no meal or water restrictions. Telehealth and pharmacy rollout follows.
Boehringer Survodutide: 16.6% weight loss at 76 weeks
SYNCHRONIZE-1 Phase 3 GLP-1 plus glucagon dual agonist with waist-circumference reduction. Adverse events mild.
Celltrion CT-P71 FDA Fast Track (April 9)
Nectin-4-targeted ADC for advanced, metastatic urothelial cancer. Korean ADC global entry signal.
NextCure SIM0505 Fast Track (April 7)
Platinum-resistant ovarian cancer ADC. April early-month U.S. oncology ADC Fast Track trend firms.
Stanford: 1 in 10 carry GLP-1 genetic resistance
Specific genetic variants blunt Ozempic and Wegovy response. Precision-medicine matching becomes critical.
FDA approves Eli Lilly Foundayo (oral GLP-1)
Average 27-pound weight loss at 72 weeks, no food or water restriction needed. Approved April 1 as the first oral GLP-1 pill.
Foundayo $25 copay for insured patients
Uninsured pricing $149β$349 per dose via LillyDirect and telehealth channels.
Novo's Wegovy pill hits 600K prescriptions in March
Novo gets a three-month market head start ahead of Foundayo, cementing early share advantage.
FDA recalls Tridergel and Revitaderm antimicrobial gels April 8
Lysinibacillus fusiformis contamination prompted voluntary lot withdrawal.
Eli Lilly acquires CrossBridge Bio for $300M on April 14
Houston-based ADC oncology startup accelerates Lilly's antibody-drug conjugate portfolio expansion.
FDA Approves Lilly's Oral GLP-1 'Foundayo' April 1 Via Fast-Track
The FDA cleared Lilly's orforglipron (brand name Foundayo) through a newly established CNP voucher fast-track pathway on April 1.
Foundayo's Out-of-Pocket Low Dose Set at $149/Month
Lilly priced Foundayo's lowest dose at $149 monthly out-of-pocket, matching Novo's Wegovy tablet pricing, BioPharma Dive reported.
Wegovy Pill Crosses 600K Prescriptions Post-Launch
Novo's Wegovy tablet tallied over 600,000 prescriptions since launch, a 10-fold faster adoption rate than the legacy Wegovy injection.
Foundayo Differentiated by Meal-Time Flexibility
Lilly's Foundayo, as a small-molecule oral drug, works regardless of meal timing, unlike Wegovy's 30-minute fasting requirement.
FDA Signals End to GLP-1 Compounding Pharmacies
STAT reported April 30 that the FDA declared GLP-1 compounding 'not clinically necessary,' signaling a market shutdown.
FDA approves Lilly 'Foundayo' (orforglipron) April 1
Once-daily oral GLP-1 for obesity in adults. No meal or time restrictions. Peak dose: 12% weight loss.
Foundayo ships; insured patients $25/month
LillyDirect dispatch starts Monday; pharmacies and telehealth follow. Uninsured: $149β349 depending on dose.
Novo Wegovy pill hits 600K March prescriptions
Novo's pill shows early momentum: 600K+ Rx in March alone. Lilly enters ~three months late.
FDA approves 42 new drugs in Q1
April 7 release of 1Q26 tally: 42 approvals. Precision oncology, metabolic disease, HIV all active.
Idvynso (doravirine-islatravir) HIV therapy expected April 21
BioPharma Dive and FDA tracker peg late-April approval for doravirine combo. Chronic infection line expands.
FDA grants priority review to Orca-T BLA for cell immunotherapy
FDA designated Orca-T, an allogeneic stem cell and T-cell immunotherapy for acute myeloid leukemia, lymphoblastic leukemia, and MDS, for priority review.
FDA approves Dapagliflozin generics and Saxagliptin-Metformin combo April 6
Drugs.com tracker: April 6 FDA approvals included Dapagliflozin 5mg and 10mg tablets plus the Saxagliptin-Metformin combination generic.
GLP-1 one-year retention falls below 25 percent; 74 percent cite restart interest
April research shows GLP-1 one-year retention below 25 percent. Separately, 74 percent of discontinuers reported willingness to restart.
Pfizer-Valneva Lyme vaccine shows 70-plus percent efficacy in Phase 3
Pfizer and Valneva reported Phase 3 VALOR study efficacy exceeding 70 percent for their Lyme vaccine candidate in ages five and up.
Ozempic may preserve lean mass better than Mounjaro
Healthline reported semaglutide (Ozempic) shows potential advantage over tirzepatide (Mounjaro) in lean mass preservation, though part of the difference stems from tirzepatide's larger weight loss magnitude.
FDA clears Foundayo (orforglipron), April 1
FDA approved Eli Lilly's once-daily oral GLP-1 Foundayo for obesity and overweight. The ATTAIN-1 trial showed 12.4% average weight loss (27.3 pounds) at the high dose. LillyDirect began shipping April 6 at $149/month out-of-pocket.
FDA converts brexu-cel (Tecartus) to standard approval
FDA converted the CAR-T cell therapy brexu-cel (Tecartus) from accelerated to standard approval for relapsed and refractory mantle-cell lymphoma, backed by ZUMA-2 long-term follow-up.
Denali's tividenofusp alfa decision due April 5
FDA was scheduled to decide on Denali Therapeutics' tividenofusp alfa for Hunter syndrome on April 5, marking a watershed moment for rare lysosomal-storage disease.
FDA Fast Track: NextCure's SIM0505 for platinum-resistant ovarian cancer
NextCure announced FDA Fast Track designation for its ADC SIM0505 in platinum-resistant ovarian cancer on April 7. Dose optimization begins Q2 2026.
AJMC: FDA speeds approvals with single-trial pathway
AJMC reported FDA now permits one clinical trial for some new-drug approvals, speeding time-to-market but raising safety-validation concerns.
FDA clears orforglipron on April 1βfirst oral small-molecule GLP-1
Eli Lilly's orforglipron earned FDA approval April 1. Once-daily oral dosing, 0.8mg starting, with a contraindication against combining with other GLP-1s. First small-molecule GLP-1 agonist for chronic weight management.
Phase 3 ATTAIN-MAINTAIN shows sustained weight loss vs. placebo
The phase 3 ATTAIN-MAINTAIN trial demonstrated orforglipron's superiority over placebo in maintaining weight loss after semaglutide or tirzepatide injection plateaus. Most common side effects: nausea, vomiting, diarrhea, constipation, indigestion.
April PDUFA calendar flags rheumatology, neurology candidates
Rheumatology Advisor and Neurology Advisor tracked April PDUFA decisions including rheumatology and neurology novel candidates. Ongoing monitoring warranted.
Iran-conflict casualties: Bandar Mahshahr toll mounting
April 4 missile strike on Bandar Mahshahr petrochemical complex killed five and wounded 170. April 3 Karaj bridge bombing wounded 100+, straining medical systems.
Bangladesh factory fire, India road crash claim six
A gas-lighter factory fire in Dakahnya, Bangladesh on April 4 killed five. A vehicle plunge near Soza, Himachal Pradesh, India same day killed four (two children) and wounded 18.
FDA greenlights Foundayo oral GLP-1 obesity pill
April 1: FDA clears Eli Lilly's orforglipron (Foundayo) for overweight and obese adults with comorbidities. No food or water restrictions, anytime dosing. ATTAIN-1 top-dose average 12.4% weight loss (~27.3 lb).
Foundayo ships via LillyDirect April 6; rapid pharmacy rollout
Foundayo accepts prescriptions April 1, ships April 6 via LillyDirect, spreading to US retail and telehealth. Cash $149/month, commercial $25/month.
Trump's 100% drug tariff carves MFN, domestic-production escape hatch
Section 232 patent drug tariffs can hit 0% through Jan 20, 2029 under MFN pricing deals or domestic production commitments; domestic entrants get 20% (100% after four years).
Lilly buys Centessa, plants neuroscience flag with OX2R agonist
Eli Lilly scoops Centessa for $6.3B upfront plus $1.5B CVR, gaining cleminorexton OX2R agonist for narcolepsy and idiopathic hypersomnia.
Project Prometheus targets drug discovery alongside robotics, aerospace
Bezos's Physical AI lab explicitly flags drug discovery alongside aerospace and robotics. Signals industrial AI's pharma R&D crossing.
FDA clears Eli Lilly's oral GLP-1 Foundayo (orforglipron) for obesity
FDA approved Eli Lilly's oral GLP-1 drug orforglipron (Foundayo) April 1 for obesity. It's the first oral GLP-1 obesity medicine with no food or water requirements and free dosingβhead-to-head to injectables Wegovy and Zepbound. Q1's most operationally impactful approval.
Pasithea PAS-004 earns Fast Track status for NF1-associated plexiform neurofibromatosis
Pasithea Therapeutics said April 1 its next-gen macrocyclic MEK inhibitor PAS-004 earned FDA Fast Track designation for NF1-associated plexiform neurofibromatosis.
A2 Bio's A2B543 autologous CAR-T earns Fast Track for MSLN-positive solid tumors
A2 Biotherapeutics announced April 1 that A2B543, an autologous CAR-T candidate, gained FDA Fast Track for relapsed/locally advanced/metastatic MSLN-expressing solid tumors in HLA-A*02-compatible adults.
Revolution Medicines' daraxonrasib doubles survival in Phase 3 pancreatic cancer trial
Revolution Medicines reported Phase 3 data: daraxonrasib plus chemotherapy extended survival to 13.2 months versus 6.7 months for chemo aloneβa 6.5-month gain.
Foundayo positioned as Q1's most operationally significant approvalβpatient demand, payer, pharmacy impact
Lumistry flagged Foundayo as Q1's most operationally impactful approval, citing patient demand, payer coverage shifts, and pharmacy dispensing potential.
FDA approves Eli Lilly oral GLP-1 'Foundayo' for obesity April 1
FDA cleared orforglipron (Foundayo) on April 1, shipping via LillyDirect starting April 6. Lowest-dose patient cash price: $149 monthly, matching Novo Nordisk's Wegovy.
FDA approves Awiqli, first once-weekly basal insulin
Drugs.com records FDA clearance of insulin icodec (Awiqli) on March 26 as the first once-weekly basal insulin for type 2 diabetes in adults.
FDA accelerates Kresladi for pediatric LAD-I
FDA granted accelerated approval to Kresladi on March 27 for pediatric severe leukocyte adhesion deficiency (LAD-I).
Eli Lilly acquires Centessa for roughly $6.3 billion
Dealroom reports Eli Lilly announced March 31 acquisition of Centessa Pharmaceuticals for approximately $6.3 billion, bolstering post-GLP-1 pipeline.
FDA accelerates Avlayah for Hunter Syndrome
Drugs.com notes FDA accelerated approval of tividenofusp alfa-eknm (Avlayah) on March 25 for Hunter Syndrome (MPS II).